US20200078474A1 - Ir dyes for fluorescence imaging - Google Patents
Ir dyes for fluorescence imaging Download PDFInfo
- Publication number
- US20200078474A1 US20200078474A1 US16/687,479 US201916687479A US2020078474A1 US 20200078474 A1 US20200078474 A1 US 20200078474A1 US 201916687479 A US201916687479 A US 201916687479A US 2020078474 A1 US2020078474 A1 US 2020078474A1
- Authority
- US
- United States
- Prior art keywords
- formula
- approximately
- compound
- hrs
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000975 dye Substances 0.000 title description 49
- 238000000799 fluorescence microscopy Methods 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000003937 drug carrier Substances 0.000 claims description 19
- 239000008223 sterile water Substances 0.000 claims description 8
- 150000001720 carbohydrates Chemical group 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940097043 glucuronic acid Drugs 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 299
- 238000000034 method Methods 0.000 description 154
- 210000000056 organ Anatomy 0.000 description 56
- 210000004185 liver Anatomy 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 33
- 239000000523 sample Substances 0.000 description 30
- 238000003384 imaging method Methods 0.000 description 29
- 210000003734 kidney Anatomy 0.000 description 29
- 150000001768 cations Chemical class 0.000 description 23
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 239000007787 solid Substances 0.000 description 20
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 18
- 229960004657 indocyanine green Drugs 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 17
- 210000003205 muscle Anatomy 0.000 description 17
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 17
- 210000000936 intestine Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 15
- 210000000626 ureter Anatomy 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 210000000232 gallbladder Anatomy 0.000 description 11
- 210000003932 urinary bladder Anatomy 0.000 description 11
- 210000000941 bile Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002059 diagnostic imaging Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- KGYHHKQTBLJKIO-UHFFFAOYSA-K CC1(C)C2=CC([Na])=CC=C2[N+](CCCCS(=O)(=O)O[Na])=C1/C=C/C1=C(OC2=CC=C(S(=O)(=O)[O-])C=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)O[Na])C3=C(C=C(S(=O)(=O)O[Na])C=C3)C2(C)C)CCC1.O=S(=O)=O Chemical compound CC1(C)C2=CC([Na])=CC=C2[N+](CCCCS(=O)(=O)O[Na])=C1/C=C/C1=C(OC2=CC=C(S(=O)(=O)[O-])C=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)O[Na])C3=C(C=C(S(=O)(=O)O[Na])C=C3)C2(C)C)CCC1.O=S(=O)=O KGYHHKQTBLJKIO-UHFFFAOYSA-K 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- -1 hydroxysuccinimide ester Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- HALIRIZNKIXDAY-UHFFFAOYSA-L CC1(C)C2=C(C=CC([Na])=C2)[N+](CCCCS(=O)(=O)O[Na])=C1/C=C/C1=C(OC2=CC=CC=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)[O-])C3=C(C=C(S(=O)(=O)O[Na])C=C3)C2(C)C)CCC1.O=S(=O)=O Chemical compound CC1(C)C2=C(C=CC([Na])=C2)[N+](CCCCS(=O)(=O)O[Na])=C1/C=C/C1=C(OC2=CC=CC=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)[O-])C3=C(C=C(S(=O)(=O)O[Na])C=C3)C2(C)C)CCC1.O=S(=O)=O HALIRIZNKIXDAY-UHFFFAOYSA-L 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000005670 electromagnetic radiation Effects 0.000 description 5
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 238000009802 hysterectomy Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- ALSDHSZKWRYBKC-UHFFFAOYSA-N 2-[(E)-2-[(3E)-3-[(2E)-2-[3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)indol-2-ylidene]ethylidene]-2-phenoxycyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-(4-sulfobutyl)indol-1-ium-5-sulfonate Chemical compound CC1(C)\C(=C\C=C2/CCCC(\C=C\C3=[N+](CCCCS(O)(=O)=O)c4ccc(cc4C3(C)C)S(O)(=O)=O)=C2Oc2ccccc2)N(CCCCS(O)(=O)=O)c2ccc(cc12)S([O-])(=O)=O ALSDHSZKWRYBKC-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000012321 colectomy Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 210000001096 cystic duct Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010046405 Ureteric injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- TVFDZZXBLUBJPY-UHFFFAOYSA-N [OH-].CC1(C)C(=CC=C2CCCC(C=CC3=[N+](CCCCS(O)(=O)=O)c4ccc(cc4C3(C)C)S(O)(=O)=O)=C2Cl)N(CCCCS(O)(=O)=O)c2ccc(cc12)S(O)(=O)=O Chemical compound [OH-].CC1(C)C(=CC=C2CCCC(C=CC3=[N+](CCCCS(O)(=O)=O)c4ccc(cc4C3(C)C)S(O)(=O)=O)=C2Cl)N(CCCCS(O)(=O)=O)c2ccc(cc12)S(O)(=O)=O TVFDZZXBLUBJPY-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- FRMYEKPWHJAHIO-UHFFFAOYSA-N nerindocianine Chemical compound CC1(C)\C(=C\C=C2/CCCC(\C=C\C3=[N+](CCCCS(O)(=O)=O)c4ccc(cc4C3(C)C)S(O)(=O)=O)=C2Oc2ccc(cc2)S(O)(=O)=O)N(CCCCS(O)(=O)=O)c2ccc(cc12)S([O-])(=O)=O FRMYEKPWHJAHIO-UHFFFAOYSA-N 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 0 CC(C)(C([*@@]1CCCCN=O)=CC=C(CCC2)C(Oc(cc3)ccc3[N+](C)(C)[O-])=C2C=CC(C(C)(C)c2c3)=*(CCCCN=O)c2ccc3N)c2c1ccc([N+](C)[O-])c2 Chemical compound CC(C)(C([*@@]1CCCCN=O)=CC=C(CCC2)C(Oc(cc3)ccc3[N+](C)(C)[O-])=C2C=CC(C(C)(C)c2c3)=*(CCCCN=O)c2ccc3N)c2c1ccc([N+](C)[O-])c2 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010878 colorectal surgery Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- SXONATFNYJWFNK-UHFFFAOYSA-M sodium;4-hydroxybenzenesulfonate;dihydrate Chemical compound O.O.[Na+].OC1=CC=C(S([O-])(=O)=O)C=C1 SXONATFNYJWFNK-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000002620 ureteric effect Effects 0.000 description 2
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ORLGPUVJERIKLW-UHFFFAOYSA-N 5-chlorotriazine Chemical compound ClC1=CN=NN=C1 ORLGPUVJERIKLW-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- JKDOKPVVPBPBDZ-UHFFFAOYSA-L CC1(C)C2=C(C=CC(S(=O)(=O)[O-])=C2)[N+](CCCCCC(=O)O)=C1/C=C/C1=C(OC2=CC=C(S(=O)(=O)[O-])C=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)O[Na])C3=C(C=C([Na])C=C3)C2(C)C)CCC1.O=S(=O)=O Chemical compound CC1(C)C2=C(C=CC(S(=O)(=O)[O-])=C2)[N+](CCCCCC(=O)O)=C1/C=C/C1=C(OC2=CC=C(S(=O)(=O)[O-])C=C2)/C(=C/C=C2/N(CCCCS(=O)(=O)O[Na])C3=C(C=C([Na])C=C3)C2(C)C)CCC1.O=S(=O)=O JKDOKPVVPBPBDZ-UHFFFAOYSA-L 0.000 description 1
- BDBMLMBYCXNVMC-UHFFFAOYSA-M CC1(C)C2=C3C=CC=CC3=CC=C2[N+](CCCCS(=O)(=O)[O-])=C1/C=C/C=C/C=C/C=C1/N(CCCCS(=O)(=O)[O-])C2=C(C3=C(C=CC=C3)C=C2)C1(C)C.[Na+] Chemical compound CC1(C)C2=C3C=CC=CC3=CC=C2[N+](CCCCS(=O)(=O)[O-])=C1/C=C/C=C/C=C/C=C1/N(CCCCS(=O)(=O)[O-])C2=C(C3=C(C=CC=C3)C=C2)C1(C)C.[Na+] BDBMLMBYCXNVMC-UHFFFAOYSA-M 0.000 description 1
- 241000229175 Calotes Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000016908 Female Genital disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 238000013264 cohort analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004891 diazines Chemical class 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002432 robotic surgery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- QAJGUMORHHJFNJ-UHFFFAOYSA-M sodium;phenoxide;trihydrate Chemical compound O.O.O.[Na+].[O-]C1=CC=CC=C1 QAJGUMORHHJFNJ-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4222—Evaluating particular parts, e.g. particular organs
- A61B5/4244—Evaluating particular parts, e.g. particular organs liver
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
- C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
- C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
- C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/10—The polymethine chain containing an even number of >CH- groups
- C09B23/107—The polymethine chain containing an even number of >CH- groups four >CH- groups
Definitions
- the present disclosure provides for methods of fluorescence imaging.
- a laparoscopic approach offers several advantages over traditional open abdominal surgery, including decreased postoperative pain, shorter hospital length of stay, fewer surgical site infections, and decreased overall hospital cost, as described in Kiran et al., “Laparoscopic approach significantly reduces surgical site infections after colorectal surgery: data from national surgical quality improvement program” J Am Coll Surg. 2010 211(2) 232-238; Bilimoria et al., “Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals” J Gastrointest Surg. 2008 12(11) 2001-2009; Juo et al., “Is Minimally Invasive Colon Resection Better Than Traditional Approaches?: First Comprehensive National Examination With Propensity Score Matching” JAMA Surg.
- Fluorescence imaging using cyanine dyes is a rapidly emerging field to support surgical navigation and provide real-time illumination of anatomic structures. Emissions in the 700-900 nm range may avoid interference from tissue auto-fluorescence and can penetrate approximately 1 cm of tissue, as described in Adams et al., “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer” J Biomed Opt. 2007 12(2), 024017; and, Keereweer et al., “Optical Image-Guided Cancer Surgery: Challenges and Limitations” Clin Cancer Res. 2013 19(14), 3745-3754.
- ICG indocyanine green
- the present invention includes a method for kidney ureter imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate compound of Formula 1:
- administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's renal system to electromagnetic radiation; and detecting fluorescence radiation from the compound.
- the method includes administering the compound of Formula 1 intravenously.
- the method includes administering the compound of Formula 1 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- the method includes administering the compound of Formula 1 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 3000.0 ⁇ g/kg and approximately 1500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1500.0 ⁇ g/kg and approximately 1000.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1000.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 500.0 ⁇ g/kg and approximately 170.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 170.0 ⁇ g/kg and approximately 120.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 120.0 ⁇ g/kg and approximately 60.0 ⁇ g/kg.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 1 remaining at the tissue of the subject's renal system at a time period after administering. In certain aspects, the methods provide visualizing the compound of Formula 1 in urine or bile.
- the method includes the measured fluorescence intensity of the administered compound of Formula 1 is background fluorescence approximately 24 hours after administering.
- the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- the method includes the measured fluorescence intensity of the administered compound of Formula 1 is higher in the kidney as compared to a measured fluorescence intensity of the administered compound of Formula 1 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
- the present invention provides a solid form (a polymorph), which is Form A of Formula 1.
- Form A of Formula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°.
- Form A has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°, about 9.6°, about 12.9°, about 18.3°, and about 20.8°.
- Form A has an X-ray powder diffraction pattern substantially as shown in FIG. 1E .
- the present invention provides a method for biliary duct imaging, comprising administering a compound of Formula 1 to a subject; and detecting fluorescence radiation from the compound.
- the invention provides a polymorph or solid form (Form A) of the compound of Formula 1 in that it provides an XRPD pattern comprising peaks substantially as set out in Table 2.
- the present invention provides a solid form (a polymorph), which is Form B of Formula 1.
- Form B of Formula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 21.2°.
- Form B has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.3°, about 14.2°, about 14.3°, about 20.7°, and about 21.2°.
- Form B has an X-ray powder diffraction pattern substantially as shown in FIG. 1H .
- the invention includes a method for liver biliary imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's liver system to electromagnetic radiation; and detecting fluorescence radiation emission from the compound.
- the method includes administering the compound of Formula 2 intravenously.
- the method includes administering the compound of Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- the method includes administering the compound of Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 ⁇ g/kg and approximately 1500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 ⁇ g/kg and approximately 1000.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 ⁇ g/kg and approximately 170.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 ⁇ g/kg and approximately 120.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 ⁇ g/kg and approximately 60.0 ⁇ g/kg.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 2 remaining at the tissue of the subject's liver system at a time period after administering.
- the methods provide visualizing the compound of Formula 2 in urine or bile.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is background fluorescence approximately 24 hours after administering.
- the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound of Formula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
- the invention includes a method for liver cystic duct imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3 ,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's liver system to electromagnetic radiation; and detecting fluorescence radiation from the compound.
- the method includes administering the compound of Formula 2 intravenously.
- the method includes administering the compound of Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- the method includes administering the compound of Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 ⁇ g/kg and approximately 1500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 ⁇ g/kg and approximately 1000.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 ⁇ g/kg and approximately 170.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 ⁇ g/kg and approximately 120.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 ⁇ g/kg and approximately 60.0 ⁇ g/kg.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 2 remaining at the tissue of the subject's liver system at a time period after administering.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is background fluorescence approximately 24 hours after administering.
- the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- the present invention provides a method for kidney ureter imaging, comprising administering a compound of Formula 2 to a subject; and detecting fluorescence radiation from the compound.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound of Formula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
- a pharmaceutical composition comprises a diagnostic imaging amount of a compound of Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprising a diagnostic imaging amount of a compound of Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier is contained in an intravenous (IV) bag.
- IV intravenous
- a pharmaceutical composition comprises a diagnostic imaging amount of a compound of Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprising a diagnostic imaging amount of a compound of Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier is contained in an intravenous (IV) bag.
- IV intravenous
- the invention includes a kit containing the pharmaceutical composition comprising a diagnostic imaging amount of a compound of Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier, and an instruction manual or instructions for use.
- the pharmaceutical composition can be contained in an intravenous (IV) bag.
- the invention includes a kit containing the pharmaceutical composition comprising a diagnostic imaging amount of a compound of Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier, and an instruction manual or instructions for use.
- the pharmaceutical composition can be contained in an intravenous (IV) bag.
- the invention includes a composition of matter comprising: 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- 800CW corresponds to the compound set forth in Comparative example 1; 800BK-sulfonate refers to compound of Formula 1; 800BK-NOS refers to compound of Formula 2.
- FIGS. 1A-1I show X-ray powder diffraction (XRPD) patterns forvarious samples. Samples shown in FIGS. 1A and 1C represent Form A. FIG. 1B is Form A, but less crystalline.
- FIG. 1D and 1E show the XRPD pattern of crystalline Form A.
- FIG. 1F shows the XRPD of the amorphous form.
- FIG. 1H and FIG. 1I show the XRPD pattern of crystalline Form B.
- FIG. 1G is identical to FIG. 1D .
- FIGS. 2A, and 2B illustrate in vitro cell-based analyses for A549 cells (A) and A431 cells (B).
- FIG. 2C shows fluorescence as a function of concentration of each dye prepared for in vivo imaging (0.03-1 ⁇ M).
- FIGS. 3A-C illustrates dorsal view fluorescence images of mice for the compound of comparative example 1 ( FIG. 3A ), the compound of Formula 1 ( FIG. 3B ), and the compound of Formula 2 ( FIG. 3C ) probes. Images are presented for the approximate time points post probe administration: 30 min, 2 hrs, 5 hrs, and 24 hrs. A Pearl® Impulse small animal imaging system was used for all animal and organ image acquisitions
- FIGS. 4A-C illustrate ventral view fluorescence images of the same mice for the compound of comparative example 1 ( FIG. 4A ); the compound of Formula 1 ( FIG. 4B ), and the compound of Formula 2 probes ( FIG. 4C ). Images are presented for the approximate time points post probe administration: 30 min, 2 hrs, 5 hrs, and 24 hrs. Arrows pinpoint bladder regional bladder signal. White arrows point to gall bladder signal.
- FIG. 5 illustrates whole body fluorescence intensity numbers for the images of FIG. 4 for the compound of comparative example 1, the compound of Formula 1, and the compound of Formula 2 probes.
- FIGS. 6A-D show fluorescence data for mouse organs for the compound of comparative example 1 ( FIG. 6A ), the compound of Formula 2 ( FIG. 6B ), the compound of Formula 1 ( FIG. 6C ): liver, spleen, intestine, brain, heart/lung, kidney, brain, and muscle ( FIG. 6D ). Fluorescence signal (800nm) adjusted to area (pixel) for all probes.
- FIG. 7 illustrates image captured of ureters, kidneys and bladder in mouse after administration of the compound of Formula 1 probe.
- FIGS. 8A-B illustrate fluorescence detection of probes in a histogram of stained electrophoresis gels of selected proteins showing non-specific or affinity of the named dyes to human (H), bovine (B), ovalbumin (O), or 5% FBS (fetal bovine serum) ( FIG. 8A ).
- dark grey represents the signal from the compound being examined
- light grey represents a Coomassie Blue assessment of protein loading
- white represents where both colors reside
- FIG. 9 illustrates fluorescent signal (800 nm) analysis of mouse urine for a control sample (no probe), the compound of Formula 1, the compound of Formula 2, and indocyanine green (ICG) dye.
- FIGS. 10A, 10B, 10C, 10D, and 10E illustrate biliary tract imaging for: 50 nmole of ICG in phosphate buffer saline (PBS) solution ( FIG. 10A ), 1 nmole of the compound of Formula 2 in PBS solution ( FIG. 10B ), 0.5 nmole of the compound of Formula 2 in PBS solution ( FIG. 10C ), and 0.1 nmole of the compound of Formula 2 in PBS solution ( FIGS. 10D and 10E).
- the imaging areas displayed for each condition were recorded at 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs., respectively (left to right).
- FIGS. 11A-11H show images of various mouse organs after administration. Fluorescence images of various mouse organs at 24 and 72 hrs post-administration for the comparative control ( FIG. 11A ), compound of Formula 1 ( FIGS. 11C and 11E ) and compound of Formula 2 ( FIG. 11B and 11D ). Organs examined included: heart (Ht), lungs (Ln), kidney (Kd), liver (Lv), spleen (Spl), intestine (Int), brain (Br), and muscle (Ms). At 24 hrs, there remains some signal in the liver and kidney but by 72 hrs the signal is diminished substantially.
- FIGS. 11F-11H show intraoperative fluorescence (800 nm, compound of Formula 2) ( FIG. 11G ), white light ( FIG. 11F ), and composite images of the liver, gall bladder, and bile duct for compound of Formula 2 (0.1 nmole) ( FIG. 11H ).
- FIG. 12 shows a spot test of the injected dye solutions-800CW, 800BK-sulfonate (compound of Formula 1; 800BK or BK) and 800BK-NOS (compound of Formula 2; 800NOS or NOS).
- FIGS. 13A-13C show whole animal imaging of dorsal and ventral view of a representative mouse injected with one of the dyes tested. Each panel of figures shows a dorsal and ventral view of the animal at 15 minutes, 1 hour, 2 hours, 4 hours 6 hours and 24 hours after injection. An animal injected with 800CW dye, 800NOS dye, and 800BK dye are shown in FIG. 13A , FIG. 13B and FIG. 13C , respectively.
- FIG. 14 shows the whole animal LUT scale, the organ 1/10 th LUT scale, and the organ 1/100 th LUT scale.
- FIGS. 15A -15D show the signal intensity of the kidney (lower left corner), liver (lower right corner), lungs (upper left corner) and muscle (upper right corner) on the organ 1/10 th LUT scale.
- Organs from an animal injected with no probe (control), 800CW dye, 800NOS dye, and 800BK dye are shown in FIG. 15A , FIG. 15B , FIG. 15C , and FIG. 15D , respectively.
- FIGS. 16A-16D show the signal intensity of the kidney (lower left corner), liver (lower right corner), lungs (upper left corner) and muscle (upper right corner) on the organ 1/100 th LUT scale.
- Organs from an animal injected with no probe (control), 800CW dye, 800NOS dye, and 800BK dye are shown in FIG. 16A , FIG. 16B , FIG. 16C , and FIG. 16D , respectively.
- a not only include aspects with one member, but also include aspects with more than one member.
- an embodiment of a method of imaging that comprises using a compound set forth herein would include an aspect in which the method comprises using two or more compounds set forth herein.
- “Balanced charge” as used herein includes the condition that the net charge for a compound and its associated counterions be zero under standard physiological conditions.
- a cationic counterion e.g., the cation of a Group I metal such as sodium
- anionic counterions must be added to balance any additional cationic groups (e.g., most basic amino groups under physiological conditions).
- cyanine dyes Some advantages include: (1) cyanine dyes strongly absorb and fluoresce light; (2) many cyanine dyes do not rapidly photo-bleach under the fluorescence microscope; (3) many structures and synthetic procedures are available and the class of dyes is versatile; and (4) cyanine dyes are relatively small (a typical molecular weight is about 1,000 daltons) so they do not cause appreciable steric interference.
- cyanine dyes are prepared according to the procedures taught in Hamer, F. M., Cyanine Dyes and Related Compounds , Weissberger, Mass., ed. Wiley Interscience, N.Y. 1964.
- cyanine dyes which contain reactive functional groups.
- U.S. Pat. Nos. 4,337,063; 4,404,289 and 4,405,711, incorporated herein by reference describe a synthesis for a variety of cyanine dyes having N-hydroxysuccinimide active ester groups.
- U.S. Pat. No. 4,981,977, incorporated herein by reference describes a synthesis for cyanine dyes having carboxylic acid groups.
- U.S. Pat. No. 5,268,486, incorporated herein by reference discloses a method for making arylsulfonate cyanine dyes.
- the present invention provides for the use of a cyanine dye of the compound having Formula 1:
- the present invention provides a solid form (a polymorph), which is Form A of Formula 1.
- Form A of Formula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°.
- Form A has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°, about 9.6°, about 12.9°, about 18.3°, and about 20.8°.
- Form A has an X-ray powder diffraction pattern substantially as shown in FIG. 1E .
- the present invention provides a solid form (a polymorph), which is Form B of Formula 1.
- Form B of Formula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 21.2°.
- Form B has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.3°, about 14.2°, about 14.3°, about 20.7° and about 21.2°.
- Form B has an X-ray powder diffraction pattern substantially as shown in FIG. 1H .
- the polymorphs of the invention are formulated into a composition prior to administration to a subject.
- the compounds of Formula 1 can exist in crystalline or noncrystalline form, or as a mixture thereof.
- pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethylacetate.
- the invention provides the sodium salt of the compound of Formula 1 incorporated into the crystalline lattice.
- the present invention provides a polymorph of the compound of Formula 1 in isolated or pure form.
- isolated or pure or “substantially pure” form refers to a sample in which the polymorph is present in an amount of >75%, particularly >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, or >99%, relative to other materials which may be present in the sample.
- the polymorphs made according to the methods of the invention can be characterized by any methodology according to the art.
- the polymorphs made according to the methods of the invention may be characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy, and spectroscopy (e.g., Raman, solid state nuclear magnetic resonance (ssNMR), and infrared (IR)).
- XRPD X-ray powder diffraction
- DSC differential scanning calorimetry
- TGA thermogravimetric analysis
- spectroscopy e.g., Raman, solid state nuclear magnetic resonance (ssNMR), and infrared (IR)
- Polymorphs according to the invention may be characterized by X-ray powder diffraction patterns (XRPD).
- XRPD X-ray powder diffraction patterns
- the relative intensities of XRPD peaks can vary, depending upon the sample preparation technique, the sample mounting procedure and the particular instrument employed. Moreover, instrument variation and other factors can affect the 2 ⁇ values. Therefore, the XRPD peak assignments can vary by plus or minus about 0.2 degrees.
- the polymorph forms of the invention are useful in the production of imaging agents and can be obtained by means of a crystallization process to produce crystalline and semi-crystalline forms.
- the crystallization is carried out by either generating the compound of Formula 1 in a reaction mixture and isolating the desired polymorph from the reaction mixture, or by dissolving raw compound in a solvent, optionally with heat, followed by crystallizing/solidifying the product by cooling (including active cooling) and/or by the addition of an antisolvent for a period of time.
- the crystallization can be followed by drying carried out under controlled conditions until the desired water content is reached in the end polymorphic form.
- the present invention provides a method of making a polymorph of a compound of Formula 1 (Form A or Form B).
- the invention is directed to methods of making a polymorph of the compound of Formula 1, wherein the method involves converting an amorphous form into a desired polymorph.
- the methods comprise exposing a composition comprising an amorphous form to conditions sufficient to convert at least about 50% of the total amount of the amorphous form into at least about 50% of the desired polymorph, and isolating the desired polymorph as needed.
- a crystalline solid will be more amenable to purification than an amorphous solid and the crystalline form is able to be made in higher purity. This is because, under proper conditions, the formation of the crystals tends to exclude impurities from the solid, in contrast to amorphous solids formed in a less controlled manner. Similarly, a crystalline solid will often have better stability than an amorphous solid, as the crystal packing gives a protective effect. For materials which are polymorphic, some crystal forms will normally be more effective than others at excluding impurities and enhancing stability.
- the present invention provides for a composition according to Formula 2:
- One embodiment of the invention includes a method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate compound of Formula 1:
- the organ includes one or more of kidney, bladder, liver, spleen, intestine, heart, lungs and muscle.
- the organ is kidney, bladder or combinations of In another embodiment, the organ is the ureter of a kidney.
- the method includes administering the compound of Formula 1 intravenously.
- the compound of Formula 1 can be administered as a bolus injection, e.g., an intravenous bolus injection.
- a bolus injection e.g., an intravenous bolus injection.
- about 5 mL to about 10 mL of a composition comprising the compound of Formula 1 is administered in a bolus injection.
- the method includes administering the compound of Formula 1 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- the method includes administering the compound of Formula 1 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- the compound of Formula 1 can be highly soluble in water.
- the compound of Formula 1 is re-suspended in water to a concentration of at least 200 mg/mL, or about 300 mg/mL to about 320 mg/mL.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 3000.0 ⁇ g/kg and approximately 1500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1500.0 ⁇ g/kg and approximately 1000.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1000.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 500.0 ⁇ g/kg and approximately 170.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 170.0 ⁇ g/kg and approximately 120.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 120.0 ⁇ g/kg and approximately 60.0 ⁇ g/kg.
- the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 30.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the compounds of Formula 1 can be non-toxic. They can absorb and fluoresce light, and do not rapidly photo-bleach under fluorescence imaging. Upon administration, the compounds of Formula 1 can be transported to tissues and organs of the subject via the natural flow of bodily fluids in the subject. As such, compounds of Formula 1 can be carried or transferred from the site of administration to the desired sites, tissues and organs for, e.g., visualization.
- the compounds and methods herein can image the biliary tract which includes any part of the liver, gall bladder, spleen, small intestine, and associated ducts.
- the biliary tract includes the intrahepatic bile ducts, cystic duct—gallbladder to common bile duct—and common bile duct—liver and gallbladder to small intestine.
- the compounds herein are found in a subject's bile or urine at a time period after administering.
- the present invention provides compositions of the compounds of Formula 1 or 2 in urine or bile.
- the methods herein provide visualizing the compounds of Formula 1 or 2 in urine or bile.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 1 remaining at the tissue of the subject's organ at a time period after administering.
- the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.
- the organ is kidney, bladder or combinations.
- the organ is the ureter of a kidney.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 1 remaining in the subject's urine or bile at a time period after administering.
- the method includes the measured fluorescence intensity of the administered compound of Formula 1 is background fluorescence approximately 24 hours after administering.
- the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, an endoscopic procedure, and an open procedure.
- the method includes the measured fluorescence intensity of the administered compound of Formula 1 is higher in the kidney as compared to a measured fluorescence intensity of the administered compound of Formula 1 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
- a pharmaceutical composition comprises a diagnostic imaging amount of a compound of Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier.
- a method for organ imaging comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- the organ includes one or more of kidney, bladder, liver, spleen, intestine, heart, lungs and muscle.
- the organ is a liver.
- the organ is the biliary duct of a liver.
- the organ is the cystic duct of a liver.
- the method includes administering the compound of Formula 2 intravenously.
- the compound of Formula 2 can be administered as a bolus injection, e.g., an intravenous bolus injection.
- a bolus injection e.g., an intravenous bolus injection.
- about 5 mL to about 10 mL of a composition comprising the compound of Formula 2 is administered in a bolus injection.
- the method includes administering the compound of Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- the method includes administering the compound of Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- the compound of Formula 2 can be highly soluble in water.
- the compound of Formula 2 is resuspended in water to a concentration of at least 200 mg/mL, about 300 mg/mL or about 320 mg/mL.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 ⁇ g/kg and approximately 1500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 ⁇ g/kg and approximately 1000.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 ⁇ g/kg and approximately 170.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 ⁇ g/kg and approximately 120.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 ⁇ g/kg and approximately 60.0 ⁇ g/kg.
- the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 30.0 ⁇ g/kg and approximately 500.0 ⁇ g/kg.
- the compounds of Formula 2 can be non-toxic. They can absorb and fluoresce light, and do not rapidly photo-bleach under fluorescence imaging. Upon administration, the compounds of Formula 2 can be transported to tissues and organs of the subject via the natural flow of bodily fluids in the subject. As such, compounds of Formula 2 can be carried or transferred from the site of administration to the desired sites, tissues and organs for, e.g., visualization.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 2 remaining at the tissue of the subject's organ system at a time period after administering.
- the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.
- the organ is the liver.
- the organ is the biliary duct of a liver.
- the organ is the cystic duct of a liver.
- the method includes measuring a fluorescence intensity of the administered compound of Formula 2 remaining in the subject's urine or bile at a time period after administering.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is background fluorescence approximately 24 hours after administering.
- the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, an endoscopic procedure, and an open procedure.
- the method includes the measured fluorescence intensity of the administered compound of Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound of Formula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering.
- a pharmaceutical composition comprises a diagnostic imaging amount of a compound of Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of compound of Formula 1 or compound of Formula 2 are in combination with a pharmaceutically acceptable cation and a pharmaceutically acceptable carrier in a diagnostic effective amount.
- the pharmaceutical composition is contained in an intravenous drip bag.
- the diagnostic effective amount of each of the compound of Formula 1 and the compound of Formula 2 is independently less than, for example, 3000.0, 2800.0, 2600.0, 2400.0, 2200.0, 2000.0, 1800.0, 1600.0, 1400.0, 1200.0, 1000.0, 950.0, 900.0, 850.0, 800.0, 750.0, 700.0, 650.0, 600.0, 550.0, 500.0, 490.0, 480.0, 470.0, 460.0, 450.0, 440.0, 430.0, 420.0, 410.0, 400.0, 390.0, 380.0, 370.0, 360.0, 350.0, 340.0, 330.0, 320.0, 310.0, 300.0, 290.0, 280.0, 270.0, 260.0, 250.0, 240.0, 230.0, 220.0, 210.0, 200.0, 190.0, 180.0, 170.0, 160.0, 150.0, 140.0, 130.0, 120.0, 110.0, 100.0, 95.0, 90.0, 85.0, 80.0, 75.0, 70.0, 65.0, 60.0, 55.0, 50.0, 49.0, 48.0,
- the diagnostic effective amount of each of the compound of Formula 1 and the compound of Formula 2 is independently greater than, for example, 2800.0, 2600.0, 2400.0, 2200.0, 2000.0, 1800.0, 1600.0, 1400.0, 1200.0, 1000.0, 950.0, 900.0, 850.0, 800.0, 750.0, 700.0, 650.0, 600.0, 550.0, 500.0, 490.0, 480.0, 470.0, 460.0, 450.0, 440.0, 430.0, 420.0, 410.0, 400.0, 390.0, 380.0, 370.0, 360.0, 350.0, 340.0, 330.0, 320.0, 310.0, 300.0, 290.0, 280.0, 270.0, 260.0, 250.0, 240.0, 230.0, 220.0, 210.0, 200.0, 190.0, 180.0, 170.0, 160.0, 150.0, 140.0, 130.0, 120.0, 110.0, 100.0, 95.0, 90.0, 85.0, 80.0, 75.0, 70.0, 65.0, 60.0, 55.0, 50.0, 49.0, 48.0, 47.0,
- the diagnostic effective amount of each of the compound of Formula 1 and the compound of Formula 2 is independently in the range from approximately 30.0 ⁇ g/kg to approximately 3000.0 ⁇ g/kg, approximately 30.1 ⁇ g/kg to approximately 2800.0 ⁇ g/kg, approximately 30.2 ⁇ g/kg to approximately 2600.0 ⁇ g/kg, approximately 30.3 ⁇ g/kg to approximately 2400.0 ⁇ g/kg, approximately 30.4 ⁇ g/kg to approximately 2200.0 ⁇ g/kg, approximately 30.5 ⁇ g/kg to approximately 2000.0 ⁇ g/kg, approximately 30.6 ⁇ g/kg to approximately 1800.0 ⁇ g/kg, approximately 30.7 ⁇ g/kg to approximately 1600.0 ⁇ g/kg, approximately 30.8 ⁇ g/kg to approximately 1400.0 ⁇ g/kg, approximately 30.9 ⁇ g/kg to approximately 1200.0 ⁇ g/kg, approximately 31.0 ⁇ g/kg to approximately 1000.0 ⁇ g/kg, approximately 31.5 ⁇ g/kg to approximately 950.0 ⁇ g/kg, approximately 32.0 ⁇ g
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 3000.0 ⁇ g/kg to approximately 1500.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 1500.0 ⁇ g/kg to approximately 1000.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 1000.0 ⁇ g/kg to approximately 500.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 500.0 ⁇ g/kg to approximately 170.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 170.0 ⁇ g/kg to approximately 120.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 120.0 ⁇ g/kg to approximately 60.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 1 is in the range from approximately 30.0 ⁇ g/kg to approximately 500.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 3000.0 ⁇ g/kg to approximately 1500.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 1500.0 ⁇ g/kg to approximately 1000.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 1000.0 ⁇ g/kg to approximately 500.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 500.0 ⁇ g/kg to approximately 170.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 170.0 ⁇ g/kg to approximately 120.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 120.0 ⁇ g/kg to approximately 60.0 ⁇ g/kg.
- the diagnostic effective amount of the compound of Formula 2 is in the range from approximately 30.0 ⁇ g/kg to approximately 500.0 ⁇ g/kg.
- the diagnostic effective amount of each of the compound of Formula 1 and the compound of Formula 2 according to the invention is effective over a wide dosage range.
- the exact dosage will depend upon the route of administration, the form in which each compound is administered, the gender, age, and body weight of the subject to be treated, and the preference and experience of the administrator.
- the fluorescence intensity of each of the administered compound of Formula 1 and the administered compound of Formula 2 may be independently measured at a time period of, for example, less than 24 hrs, 23 hrs, 22 hrs, 21 hrs, 20 hrs, 19 hrs, 18 hrs, 17 hrs, 16 hrs, 15 hrs, 14 hrs, 13 hrs, 12 hrs, 11 hrs, 10 hrs, 9.5 hrs, 9.0 hrs, 8.5 hrs, 8.0 hrs, 7.5 hrs, 7.0 hrs, 6.5 hrs, 6.0 hrs, 5.5 hrs, 5.0 hrs, 4.75 hrs, 4.50 hrs, 4.25 hrs, 4.00 hrs, 3.75 hrs, 3.50 hrs, 3.25 hrs, 3.00 hrs, 2.75 hrs, 2.50 hrs, 2.25 hrs, 2.00 hrs, 1.75 hrs, 1.50 hrs, 1.25 hrs, 1.00 hrs, 0.90 hrs, 0.80 hrs, 0.70 hrs, 0.60 hrs, 0.50 hrs, 0.70
- the fluorescence intensity of each of the administered compound of Formula 1 and the administered compound of Formula 2 may be independently measured at a time period of, for example, greater than 23 hrs, 22 hrs, 21 hrs, 20 hrs, 19 hrs, 18 hrs, 17 hrs, 16 hrs, 15 hrs, 14 hrs, 13 hrs, 12 hrs, 11 hrs, 10 hrs, 9.5 hrs, 9.0 hrs, 8.5 hrs, 8.0 hrs, 7.5 hrs, 7.0 hrs, 6.5 hrs, 6.0 hrs, 5.5 hrs, 5.0 hrs, 4.75 hrs, 4.50 hrs, 4.25 hrs, 4.00 hrs, 3.75 hrs, 3.50 hrs, 3.25 hrs, 3.00 hrs, 2.75 hrs, 2.50 hrs, 2.25 hrs, 2.00 hrs, 1.75 hrs, 1.50 hrs, 1.25 hrs, 1.00 hrs, 0.90 hrs, 0.80 hrs, 0.70 hrs, 0.60 hrs, 0.50 hrs, 0.40
- the fluorescence intensity of each of the administered compound of Formula 1 and the administered compound of Formula 2 may be independently measured at a time period in the range from approximately 0.10 hrs to approximately 24 hrs, approximately 0.20 hrs to approximately 23 hrs, approximately 0.30 hrs to approximately 22 hrs, approximately 0.40 hrs to approximately 21 hrs, approximately 0.50 hrs to approximately 20 hrs, approximately 0.60 hrs to approximately 19 hrs, approximately 0.70 hrs to approximately 18 hrs, approximately 0.80 hrs to approximately 17 hrs, approximately 0.90 hrs to approximately 16 hrs, approximately 1.00 hr to approximately 15 hrs, approximately 1.25 hrs to approximately 14 hrs, approximately 1.50 hrs to approximately 13 hrs, approximately 1.75 hrs to approximately 12 hrs, approximately 2.00 hrs to approximately 11 hrs, approximately 2.25 hrs to approximately 10 hrs, approximately 2.50 hrs to approximately 9.5 hrs, approximately 2.75 hrs to approximately 9.0 hrs, approximately 3.00 hrs to approximately 8.5 hrs, approximately 3.25 hrs to approximately 8.0 hrs, approximately 3.
- the sample is illuminated with a wavelength of light selected to give a detectable optical response, and observed with a means for detecting the optical response.
- Equipment that is useful for illuminating the dye compounds of the invention includes, but is not limited to, tungsten lamps, hand-held ultraviolet lamps, mercury arc lamps, xenon lamps, light emitting diodes (LED), lasers and laser diodes. These illumination sources are optionally integrated into surgical cameras, laparoscopes and microscopes.
- Preferred embodiments of the invention are dyes that are excitable at or near the wavelengths 633-636 nm, 647 nm, 660 nm, 680 nm and beyond 700 nm, such as 780 nm, 810 nm and 850 nm as these regions closely match the output of relatively inexpensive excitation sources.
- the optical response is optionally detected by visual inspection, or by use of any of the following devices: CCD cameras, video cameras, photographic film.
- the NIR imaging probe used was the compound of Formula 1; excitation 773 nm and emission 790 nm or independently, Formula 2, excitation 772 nm and emission 787 nm.
- the compound of Formula 1 and the compound of Formula 2 as described herein can be administered in a manner compatible with the dosage formulation, and in such amount as will be effective or suitable for in vivo imaging.
- the quantity to be administered depends on a variety of factors including, e.g., the age, body weight, physical activity, and diet of the individual, the tissue or organ to be imaged, and type of procedure or surgery to be performed.
- the size of the dose may also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of the compound in a particular individual.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, hereditary characteristics, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- the dose may take the form of solid, semi-solid, or lyophilized powder forms, preferably in unit dosage forms suitable for simple administration of precise dosages.
- the dose is provided in a container, vial or syringe at a particular dosage for one or more administrations.
- unit dosage form refers to physically discrete units suitable as unitary dosages for humans and other mammals, each unit containing a predetermined quantity of an imaging agent calculated to produce the desired onset, tolerability, and/or fluorescent effects, in association with a suitable pharmaceutical excipient (e.g., an ampoule).
- a suitable pharmaceutical excipient e.g., an ampoule
- more concentrated dosage forms may be prepared, from which the more dilute unit dosage forms may then be produced.
- the more concentrated dosage forms thus will contain substantially more than, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times the amount of the imaging agent.
- the dosage forms typically include a conventional pharmaceutical carrier or excipient and may additionally include other medicinal agents, carriers, adjuvants, diluents, tissue permeation enhancers, solubilizers, and the like.
- Appropriate excipients can be tailored to the particular dosage form and route of administration by methods well known in the art (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ED., Mack Publishing Co., Easton, Pa. (1990)).
- the dosage forms contain a stabilizing agent for the storage, isolation, purification, and/or lyophilization of the compounds.
- Agents for lyophilization include, but are not limited to, a saccharide such as a monosaccharide, a disaccharide or dextran.
- Other saccharides include glucose, galactose, xylose, glucuronic acid, trehalose, dextran, hydroxyethyl starch, mannitol, or 5% dextrose.
- the effective dose can be in the form of sterile injectable solutions and sterile packaged powders.
- injectable solutions are formulated at a pH of from about 4.5 to about 7.5, or physiological pH.
- the effective dose for imaging contains a lyophilized compound described herein in a high-quality, easily dissolved form which is stable for months at room temperature.
- the lyophilized compound of Formula 1 or Formula 2 can be stored in any suitable type of sealed container, such as a sealed vial or syringe that contains an amount of the compound for a single dosage for a subject, such as a human adult.
- the term “vial” is used broadly herein, to refer to any drug-packaging device that is designed and suitable for sealed and sterile storage, shipping, and handling of small (e.g., single-dosage) quantities of drugs.
- Single-chamber vials (which would contain only the lyophilized compound, with no water) are well known; a typical single-chamber vial may be designed for use with an intravenous infusion bag. Alternatively, two-chamber vials can be used that contain both the lyophilized compound and a sterile aqueous solution, to enable immediate reconstitution and injection of an aqueous liquid containing the compound of Formula 1 or Formula 2.
- a kit comprises one or more vials or syringes containing compound of Formula 1 in, for example, a lyophilized form.
- a kit comprises one or more vials or syringes containing compound of Formula 2 in, for example, a lyophilized form.
- kits can also include a pharmaceutically acceptable carrier or a sterile aqueous solution, e.g., sterile water for reconstituting the compound prior to administration.
- the kit also includes a sterile syringe for parenteral administration of the compound or for use with an intravenous infusion bag.
- the kit can also include an instruction manual for use.
- the compound of Formula 1 may be synthesized by dissolving 3,3-Dimethyl-2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-5-sulfo-1-(4-sulfobutyl)-3H-indolium hydroxide, innersalt, trisodium salt (1 g, 1.05 mmol) in 25 mL of water and sparging with nitrogen for 15 minutes.
- the polymorph of the compound of Formula 1 (Form A) can be prepared as follows:
- XRPD analysis was carried out on a PANalytical X'pert pro, scanning the samples between 3 and 35° 20. The material was gently ground and loaded onto a multiwell plate with
- the multiwell plate was then loaded into a Panalytical diffractometer running in transmission mode and analyzed.
- FIG. 1A-1F The XRPD data are shown in FIG. 1A-1F .
- FIG. 1A and 1C are identical and are both moderately crystalline and represent Form A.
- FIG. 1B is similar in crystallinity and is Form A.
- FIG. 1D is crystalline.
- FIG. 1E is an enlargment of FIG. 1D .
- FIG. 1D and FIG. 1E represent Form A.
- FIG. 1F is the amorphous form.
- Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 1 for Form A. Peak positions were measured and tabulated.
- Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 2 for Form A. Peak positions were measured and tabulated.
- Form B it is possible to make Form B from Form A.
- Form A is crystalline and exists as small birefringent particles with no defined morphology.
- the material is hygroscopic (27 wt % uptake up-to 90%RH) and can change form under stress conditions.
- a form change does occur when Form A is subjected to 40° C./75% RH. This form corresponds with the form found with the post-GVS sample. HPLC purity showed no change.
- FIG. 1H and FIG. 1I represent Form B.
- FIG. 1G is identical to FIG. 1D .
- Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 3 for Form B. Peak positions were measured and tabulated.
- the compound of Formula 2 may be synthesized by dissolving 3,3-Dimethyl-2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-5-sulfo-1-(4-sulfobutyl)-3H-indolium hydroxide, innersalt, trisodium salt (1 g, 1.05 mmol) in 25 mL of water and sparging with nitrogen for 15 minutes.
- ICG indocyanine green
- the compound of Formula 2 demonstrated a significant increase in non-specific binding compared to either the compound of Formula 1 and 800CW by two-fold.
- the compound of Formula 1 was more comparable to 800CW.
- FIG. 2C shows that all three compounds in this test were very close in fluorescence, thus confirming that the increased fluorescence at higher concentrations noted in plate-based assay is likely due to a tendency of the compound to bind non-specifically to cells.
- the compound of comparative example 1 is used as the reference. From the Dorsal view there is no kidney signal for any probe. At 2 hrs post injection, the compound of Formula 2 exhibits high signal, emanating in the liver region visible from the back. The compound of Formula 2 never fully disseminates because it is collected rapidly in the liver and by 5 hr post injection, the whole body signal is low compared to 800CW and the compound of Formula 1.
- Ventral images are presented in FIG. 4 . From visual examination, the compound of Formula 1 and 800CW are similar in their clearance pattern. These two probes appear to clear rapidly via the kidney. This feature is very useful for imaging the urinary system.
- the compound of Formula 2 clears through the liver. This feature is a very useful attribute for a biliary duct monitoring dye which may “mimic” ICG that is currently used for this clinical application. From the in vitro plate-based assays it appeared both the compound of Formula 1 and the compound of Formula 2 have similar fluorescence intensities to 800CW. However, from the in vivo data, it appeared that the compound of Formula 1 moves rapidly through the tissues but is retained for an extended period in organs.
- Bladder signal is the strongest signal noted for 800CW and the compound of Formula 1 probes (purple arrows).
- Another way of examining fluorescence signals is by measuring the % of the compound remaining at a particular time point.
- the 30 min time point is the baseline to which other time points are normalized. This data are presented below in Table 4.
- the percent signal remaining at each time is shown with the 30 min time point post-injection, which is used as the baseline.
- the compound of Formula 1 is very similar to 800CW and by 24 hrs post injection, all compounds are very similar in remaining signals at less than 2% of baseline.
- the compound of Formula 1 is retained at higher levels in the liver and kidney compared to the compound of Formula 2 at 24 hrs post injection. Surprisingly, the compound of Formula 2, which clears predominantly from the liver, has lower liver signals at 24 hrs when compared to 800CW and the compound of Formula 1. This may be explained by a slower overall clearance from tissue for the compound of Formula 1 as compared to 800CW and the compound of Formula 2.
- FIG. 7 illustrates the ureters along with kidney and bladder.
- FIG. 8 illustrates fluorescence images of stained electrophoresis gels of selected proteins showing non-specific or affinity of the named compounds to human (H), bovine (B), ovalbumin (O), or 5% FBS (fetal bovine serum). It is clear that the compound of Formula 2 has potential to be useful for biliary duct examinations, similar to ICG.
- FIGS. 10A and 10B A comparison between the compound of Formula 2 and ICG was conducted for their common application in imaging the biliary duct ( FIGS. 10A and 10B ).
- a Pearl Impulse small animal imaging system was used for all animal and organ image acquisitions.
- ICG is not very soluble in aqueous media and gives a much weaker fluorescent signal than the compound of Formula 2 in vivo.
- a 50 nmole solution of ICG in phosphate buffer saline solution was prepared, injected intravenously, and compared for localization with a 1 nmole solution of the compound of Formula 2 at time periods of 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs.
- FIG. 10B A comparison of the dose responses for the compound of Formula 2 are shown in FIG. 10B (1 nmole), FIG. 10C (0.5 nmole), and FIGS. 10D and 10E (0.1 nmole) at time periods of 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs. All images are presented using the same LUT table except FIG. 10E where the LUT for FIG. 10D has been reduced to brighten the 800nm signal so they are visible.
- the gall bladder is visible by 30 min post-intravenous administration for the 1 nmole ( FIG. 10B ) and 0.5 nmole ( FIG. 10C ) doses and continues to be visible in the 2 hrs and 5 hrs images.
- the images for the 0.1 nmole dose in FIG. 10D appear to show very low detection signal using the same scale as the 1 nmole and 0.5 nmole dose series.
- the scale is adjusted as in FIG. 10E , the gall bladder target region is visible on a very low background.
- a wide range of dosing is possible to accommodate a particular imaging system or application.
- Fluorescent signal intensities of various organs were examined at 24 hrs and 72 hrs for the compound of Formula 1 and the compound of Formula 2 ( FIG. 11A-11E ).
- Organs examined included: heart (Ht), lungs (Ln), kidney (Kd), liver (Lv), spleen (Spl), intestine (Int), brain (Br), and muscle (Ms).
- Ht heart
- lungs Ln
- kidney Kd
- liver Lv
- Spl spleen
- intestine Int
- brain brain
- Ms muscle
- FIG. 11A shows the results using the control (800CW), 24 hours post administration.
- FIG. 11B shows the results using a compound of Formula 2, 24 hours post administration.
- FIG. 11C shows the results using a compound of Formula 1, 24 hours post administration.
- FIG. 11D-11E show the results 72 hours post administration of Formula 2 and Formula 1, respectively.
- FIG. 11F shows a surgically opened animal for determining whether biliary structures are visible.
- the animal's liver was positioned to expose the critical structures.
- the image series of FIG. 11F-11H present the white light image of the liver with lobes raised to expose the gall bladder and biliary duct associated with Calot's triangle; the 800 nm image as detected by fluorescence studies of a compound of Formula 2; and a composite image overlaying the 800 nm image atop the white light image.
- This example describes an experiment to evaluate the excretion of the dyes described herein from animals injected with such.
- the dyes tested were stable cyanine dyes (IRdyes): 800CW, 800BK-sulfonate (compound of Formula 1; 800BK or BK) and 800BK-NOS (compound of Formula 2; 800NOS or NOS).
- 12 nude mice (3 per treatment group) were injected with either (1) no probe (control group); (2) 800CW; (3) 800NOS; or (4) 800BK.
- the three probes 800CW-1166 g/mole (should have been 1091.1 g/mole), 800NOS-1011.09 g/mole, and 800BK-1113.14 g/mole) were dissolved in PBS.
- a spot test of the three probes was performed to detect the fluorescent signal when diluted to the injection dose of 1 nmole/100 ⁇ l ( FIG. 12 ).
- the fluorescence of 800CW was slightly higher than that of 800NOS and 800BK
- a representative series of images are presented in FIGS. 13A -13C of one animal per dye. All the data was normalized to the same LUT.
- a control mouse (no probe) was used as a reference (no signal control). Imaging was performed using the Pearl® Trilogy Imaging System (LI-COR®).
- mice were then sacrificed and their organs and tissue (i.e., liver, kidney, lungs, spleen and muscle) were harvested.
- organs and tissue i.e., liver, kidney, lungs, spleen and muscle
- the organs were imaged to detect fluorescence.
- fluorescence in the organs was not detectable.
- the low end of the animal scale was expanded such that the images of the organs could be evaluated ( FIG. 14 ).
- the “Organs 1/10th scale” was used for the images of FIGS. 15A-15D and the “Organs 1/100 th scales was used for the images of FIGS. 16A-16D .
- FIG. 15A shows no fluorescence in the organs of the control animal. Kidneys (lower left corner) and liver (lower right corner) had a detectable signal in the animals treated with 800CW ( FIG. 15B ), 800NOS ( FIG. 15C ), and 800BK ( FIG. 15D ). No muscle (top right corner) or lung tissue (top left corner) was visible in the treatments except for the 800CW treatment. At the 1/10th LUT scale, the high level is 1/10th that of the whole animal LUT scale. The data shows that there is only residual dye remaining in these organs when imaging at the whole animal LUT scale.
- FIGS. 16A-D show some signal in the organs if the whole animal LUT scale is reduced to 100 ⁇ such that the adjusted scale is 1/100th the whole animal scale.
- FIG. 16A shows the signal from the control animal.
- FIGS. 16B, 16C and 16D shows the signal from organs of the 800CW treated animal, the 800NOS treated animal and the 800BK treated animal, respectively.
- 800CW and 800BK was excreted renally.
- the higher overall signal in the 800CW animals is mainly due to the accidentally higher concentration of the probe injected into the animals.
- 800NOS was eliminated from the body via the biliary tract (liver, gall bladder and bile ducts) and intestines.
- the liver was visible at 15 minutes and then the gall bladder, as the dye rapidly left the liver.
- the data also showed that the dye was moved into the intestines for excretion.
- the predominant signal between 2-6 hours was in the intestines. At 24 hours post injection the intestinal signal was barely detectable.
- the organs were imaged under three LUT scales; each being progressively smaller in the signal range covered. The lower levels of each progressive scale were expanded to cover the full red to blue color range ( FIG. 14 ). Very little signal remained in any of the target organs such as liver, kidney, lungs and muscle. Similar signal intensities were found in the kidney for 800CW and 800BK. In the liver, 800BK had a higher signal compared to 800CW. The results show that 800BK has a longer retention time in the liver compared to 800CW and 800NOS. This may be due to increased (higher) plasma protein binding of 800BK than 800CW.
- the pharmaceutical formulation of Formula 1 is dissolved in a vial (25 mg) with 5 mL of saline (0.9% sodium chloride) and is administered to a patient via a bolus injection at the concentration of 5 mg/mL, 15 minutes prior to the surgery.
- the medical device for this procedure is the PINPOINT Endoscopic Fluorescence Imaging System (Novadaq, Mississauga, Ontario, Canada).
- the device's mode is switched to the near-infrared detection imaging, and the surgeon visualizes the ureter via the monitor or display of the medical device. This identification of the ureter is visualized on the monitor as an overlay image, in which the surgeon can simultaneously locate the ureter with white light imaging.
- the pharmaceutical formulation of Formula 2 is dissolved in a vial (25 mg) with 5 mL of saline (0.9% sodium chloride) and is administered to a patient via a bolus injection at the concentration of 5 mg/mL, 15 minutes prior to the surgery starting.
- the medical device for this procedure is the da Vinci Firefly Surgical System (Intuitive Surgical, Sunnyvale Calif.).
- the device's mode is switched to the near-infrared detection imaging, and the surgeon identifies the biliary duct via the monitor or display of the medical device by switching between the white light image and the near-infrared image as needed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 14/949,654 filed Nov.23, 2015, allowed, which application claims priority to U.S. Provisional Patent Application No. 62/084,971, filed Nov. 26, 2014, the teachings of which are hereby incorporated by reference in their entities for all purposes.
- The present disclosure provides for methods of fluorescence imaging.
- Conventional laparoscopic and robotic laparoscopic techniques are both rapidly growing practices in the fields of colorectal and gynecologic surgery. Recent studies as described in Simorov et al., “Laparoscopic colon resection trends in utilization and rate of conversion to open procedure: a national database review of academic medical centers” Ann Surg. 2012 256(3), 462-468; Wright et al., “Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease” JAMA 2013 309(7), 689-698; and, Park et al., “Ureteral injury in gynecologic surgery: a 5-year review in a community hospital” Korean J. Urol. 2012 53(2), 120-125, report 42% of all colorectal resections and greater than 30% of gynecologic procedures are attempted in this manner.
- A laparoscopic approach offers several advantages over traditional open abdominal surgery, including decreased postoperative pain, shorter hospital length of stay, fewer surgical site infections, and decreased overall hospital cost, as described in Kiran et al., “Laparoscopic approach significantly reduces surgical site infections after colorectal surgery: data from national surgical quality improvement program” J Am Coll Surg. 2010 211(2) 232-238; Bilimoria et al., “Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals” J Gastrointest Surg. 2008 12(11) 2001-2009; Juo et al., “Is Minimally Invasive Colon Resection Better Than Traditional Approaches?: First Comprehensive National Examination With Propensity Score Matching” JAMA Surg. 2014 149(2) 177-184; Wilson et al., “Laparoscopic colectomy is associated with a lower incidence of postoperative complications compared with open colectomy: a propensity score-matched cohort analysis” Colorectal Dis. 2014 16(5) 382-389; Kobayashi etal., “Total laparoscopic hysterectomy in 1253 patients using an early ureteral identification technique” J Obstet Gynaecol Res. 2012 38(9) 1194-1200; Makinen et al., “Ten years of progress--improved hysterectomy outcomes in Finland 1996-2006: a longitudinal observation study” BMJ Open 2013 3(10) e003169.
- However, limited tactile sensation and two-dimensional images can lead to iatrogenic ureter injury. Although infrequent, laparoscopic ureter injury remains a serious complication with significant associated morbidity. Reports indicate an incidence between 0.1-7.6% for colorectal and gynecologic surgery with more than 80% of these failing to be recognized intraoperatively, as described in Park et al.; Palaniappa et al., “Incidence of iatrogenic ureteral injury after laparoscopic colectomy” Arch Surg. 2012 147(3), 267-271; and, da Silva et al., “Role of prophylactic ureteric stents in colorectal surgery” Asian J Endosc Surg. 2012 5(3), 105-110. Current techniques for intraoperative ureter identification include ureteral stent placement, x-ray fluoroscopy, and visible dyes; however, both stents and fluoroscopy carry additional risk to the patient, and visible dyes are often not sensitive, as described in Tanaka et al., “Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence” J Urol. 2007 178(5), 2197-2202; Bothwell et al., “Prophylactic ureteral catheterization in colon surgery. A five-year review” Dis Colon Rectum. 1994 37(4), 330-334; Wood et al., “Routine use of ureteric catheters at laparoscopic hysterectomy may cause unnecessary complications” J Am Assoc Gynecol Laparosc. 1996 3(3), 393-397; and, Brandes et al., “Diagnosis and management of ureteric injury: an evidence-based analysis” BJU Int. 2004 94(3), 277-289.
- Fluorescence imaging using cyanine dyes is a rapidly emerging field to support surgical navigation and provide real-time illumination of anatomic structures. Emissions in the 700-900 nm range may avoid interference from tissue auto-fluorescence and can penetrate approximately 1 cm of tissue, as described in Adams et al., “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer” J Biomed Opt. 2007 12(2), 024017; and, Keereweer et al., “Optical Image-Guided Cancer Surgery: Challenges and Limitations” Clin Cancer Res. 2013 19(14), 3745-3754.
- Another application of fluorescence imaging is for the real-time intra-operative imaging of the biliary anatomy, including the biliary duct and cystic duct. Current methods often use indocyanine green (ICG) dye by either intra-biliary injection or intravenous injection before surgery. However, studies have shown clear problems in using ICG dye. These include poor efficiency and kinetics of excretion into bile (Tanaka et al., “Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light” Surgery 2008 144(1) 39-48) and adverse reaction with the patient (Benya et al., “Adverse reactions to indocyanine green: a case report and a review of the literature” Cathet Cardiovasc Diagn. 1989 17(4) 231-233).
- There exists a need for sensitive compositions and methods to detect and measure an internal target non-invasively. Specifically, there exists a need for improved, stable cyanine dyes to detect injuries to various organs that may occur during laparoscopic or robotic surgery. The present invention satisfies these and other needs.
- BRIEF SUMMARY OF THE INVENTION
- In an embodiment, the present invention includes a method for kidney ureter imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate compound of Formula 1:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation, wherein the administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's renal system to electromagnetic radiation; and detecting fluorescence radiation from the compound.
- In one embodiment, the method includes administering the compound of
Formula 1 intravenously. - In one embodiment, the method includes administering the compound of Formula 1 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- In one embodiment, the method includes administering the compound of Formula 1 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 3000.0 μg/kg and approximately 1500.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1500.0 μg/kg and approximately 1000.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1000.0 μg/kg and approximately 500.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 500.0 μg/kg and approximately 170.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 170.0 μg/kg and approximately 120.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 1 at a diagnostic effective amount of the compound ranging between approximately 120.0 μg/kg and approximately 60.0 μg/kg.
- In one embodiment, the method includes measuring a fluorescence intensity of the administered compound of
Formula 1 remaining at the tissue of the subject's renal system at a time period after administering. In certain aspects, the methods provide visualizing the compound of Formula 1 in urine or bile. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of Formula 1 is background fluorescence approximately 24 hours after administering.
- In one embodiment, the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 1 is higher in the kidney as compared to a measured fluorescence intensity of the administered compound ofFormula 1 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering. - In one embodiment, the present invention provides a solid form (a polymorph), which is Form A of
Formula 1. Form A ofFormula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°. Form A has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°, about 9.6°, about 12.9°, about 18.3°, and about 20.8°. Form A has an X-ray powder diffraction pattern substantially as shown inFIG. 1E . - In one embodiment, the present invention provides a method for biliary duct imaging, comprising administering a compound of
Formula 1 to a subject; and detecting fluorescence radiation from the compound. - In another embodiment, the invention provides a polymorph or solid form (Form A) of the compound of
Formula 1 in that it provides an XRPD pattern comprising peaks substantially as set out in Table 2. - In one embodiment, the present invention provides a solid form (a polymorph), which is Form B of
Formula 1. Form B ofFormula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 21.2°. Form B has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.3°, about 14.2°, about 14.3°, about 20.7°, and about 21.2°. Form B has an X-ray powder diffraction pattern substantially as shown inFIG. 1H . - In an embodiment, the invention includes a method for liver biliary imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation, wherein the administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's liver system to electromagnetic radiation; and detecting fluorescence radiation emission from the compound.
- In one embodiment, the method includes administering the compound of
Formula 2 intravenously. - In one embodiment, the method includes administering the compound of Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium.
- In one embodiment, the method includes administering the compound of Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution.
- In one embodiment, the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 μg/kg and approximately 1500.0 μg/kg.
- In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 μg/kg and approximately 1000.0 μg/kg. - In one embodiment, the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 μg/kg and approximately 500.0 μg/kg.
- In one embodiment, the method includes administering the compound of Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 μg/kg and approximately 170.0 μg/kg.
- In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 μg/kg and approximately 120.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 μg/kg and approximately 60.0 μg/kg. - In one embodiment, the method includes measuring a fluorescence intensity of the administered compound of
Formula 2 remaining at the tissue of the subject's liver system at a time period after administering. - In certain aspects, the methods provide visualizing the compound of
Formula 2 in urine or bile. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is background fluorescence approximately 24 hours after administering. - In one embodiment, the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound ofFormula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering. - In an embodiment, the invention includes a method for liver cystic duct imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3 ,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation, wherein the administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's liver system to electromagnetic radiation; and detecting fluorescence radiation from the compound.
- In one embodiment, the method includes administering the compound of
Formula 2 intravenously. - In one embodiment, the method includes administering the compound of
Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium. - In one embodiment, the method includes administering the compound of
Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 μg/kg and approximately 1500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 μg/kg and approximately 1000.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 μg/kg and approximately 500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 μg/kg and approximately 170.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 μg/kg and approximately 120.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 μg/kg and approximately 60.0 μg/kg. - In one embodiment, the method includes measuring a fluorescence intensity of the administered compound of
Formula 2 remaining at the tissue of the subject's liver system at a time period after administering. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is background fluorescence approximately 24 hours after administering. - In one embodiment, the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, and an open procedure.
- In one embodiment, the present invention provides a method for kidney ureter imaging, comprising administering a compound of
Formula 2 to a subject; and detecting fluorescence radiation from the compound. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound ofFormula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering. - In one embodiment, a pharmaceutical composition comprises a diagnostic imaging amount of a compound of
Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier. - In one embodiment, the pharmaceutical composition comprising a diagnostic imaging amount of a compound of
Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier is contained in an intravenous (IV) bag. - In one embodiment, a pharmaceutical composition comprises a diagnostic imaging amount of a compound of
Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier. - In one embodiment, the pharmaceutical composition comprising a diagnostic imaging amount of a compound of
Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier is contained in an intravenous (IV) bag. - In one embodiment, the invention includes a kit containing the pharmaceutical composition comprising a diagnostic imaging amount of a compound of
Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier, and an instruction manual or instructions for use. The pharmaceutical composition can be contained in an intravenous (IV) bag. - In other embodiments, the invention includes a kit containing the pharmaceutical composition comprising a diagnostic imaging amount of a compound of
Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier, and an instruction manual or instructions for use. The pharmaceutical composition can be contained in an intravenous (IV) bag. - In an embodiment, the invention includes a composition of matter comprising: 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation.
- Other embodiments, aspects, and objects will become better understood when read with the detailed description and drawings which follow.
- In each of the drawings 800CW corresponds to the compound set forth in Comparative example 1; 800BK-sulfonate refers to compound of
Formula 1; 800BK-NOS refers to compound ofFormula 2. -
FIGS. 1A-1I show X-ray powder diffraction (XRPD) patterns forvarious samples. Samples shown inFIGS. 1A and 1C represent Form A.FIG. 1B is Form A, but less crystalline. -
FIG. 1D and 1E show the XRPD pattern of crystalline Form A.FIG. 1F shows the XRPD of the amorphous form.FIG. 1H andFIG. 1I show the XRPD pattern of crystalline Form B. For comparison,FIG. 1G is identical toFIG. 1D . -
FIGS. 2A, and 2B illustrate in vitro cell-based analyses for A549 cells (A) and A431 cells (B).FIG. 2C shows fluorescence as a function of concentration of each dye prepared for in vivo imaging (0.03-1 μM). -
FIGS. 3A-C illustrates dorsal view fluorescence images of mice for the compound of comparative example 1 (FIG. 3A ), the compound of Formula 1 (FIG. 3B ), and the compound of Formula 2 (FIG. 3C ) probes. Images are presented for the approximate time points post probe administration: 30 min, 2 hrs, 5 hrs, and 24 hrs. A Pearl® Impulse small animal imaging system was used for all animal and organ image acquisitions -
FIGS. 4A-C illustrate ventral view fluorescence images of the same mice for the compound of comparative example 1 (FIG. 4A ); the compound of Formula 1 (FIG. 4B ), and the compound ofFormula 2 probes (FIG. 4C ). Images are presented for the approximate time points post probe administration: 30 min, 2 hrs, 5 hrs, and 24 hrs. Arrows pinpoint bladder regional bladder signal. White arrows point to gall bladder signal. -
FIG. 5 illustrates whole body fluorescence intensity numbers for the images ofFIG. 4 for the compound of comparative example 1, the compound ofFormula 1, and the compound ofFormula 2 probes. -
FIGS. 6A-D show fluorescence data for mouse organs for the compound of comparative example 1 (FIG. 6A ), the compound of Formula 2 (FIG. 6B ), the compound of Formula 1 (FIG. 6C ): liver, spleen, intestine, brain, heart/lung, kidney, brain, and muscle (FIG. 6D ). Fluorescence signal (800nm) adjusted to area (pixel) for all probes. -
FIG. 7 illustrates image captured of ureters, kidneys and bladder in mouse after administration of the compound ofFormula 1 probe. -
FIGS. 8A-B illustrate fluorescence detection of probes in a histogram of stained electrophoresis gels of selected proteins showing non-specific or affinity of the named dyes to human (H), bovine (B), ovalbumin (O), or 5% FBS (fetal bovine serum) (FIG. 8A ). In the fluorescence images of stained electrophoresis gels dark grey represents the signal from the compound being examined, light grey represents a Coomassie Blue assessment of protein loading and white represents where both colors reside (FIG. 8B ). -
FIG. 9 illustrates fluorescent signal (800 nm) analysis of mouse urine for a control sample (no probe), the compound ofFormula 1, the compound ofFormula 2, and indocyanine green (ICG) dye. -
FIGS. 10A, 10B, 10C, 10D, and 10E illustrate biliary tract imaging for: 50 nmole of ICG in phosphate buffer saline (PBS) solution (FIG. 10A ), 1 nmole of the compound ofFormula 2 in PBS solution (FIG. 10B ), 0.5 nmole of the compound ofFormula 2 in PBS solution (FIG. 10C ), and 0.1 nmole of the compound ofFormula 2 in PBS solution (FIGS. 10D and 10E). The imaging areas displayed for each condition were recorded at 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs., respectively (left to right). -
FIGS. 11A-11H show images of various mouse organs after administration. Fluorescence images of various mouse organs at 24 and 72 hrs post-administration for the comparative control (FIG. 11A ), compound of Formula 1 (FIGS. 11C and 11E ) and compound of Formula 2 (FIG. 11B and 11D ). Organs examined included: heart (Ht), lungs (Ln), kidney (Kd), liver (Lv), spleen (Spl), intestine (Int), brain (Br), and muscle (Ms). At 24 hrs, there remains some signal in the liver and kidney but by 72 hrs the signal is diminished substantially.FIGS. 11F-11H show intraoperative fluorescence (800 nm, compound of Formula 2) (FIG. 11G ), white light (FIG. 11F ), and composite images of the liver, gall bladder, and bile duct for compound of Formula 2 (0.1 nmole) (FIG. 11H ). -
FIG. 12 shows a spot test of the injected dye solutions-800CW, 800BK-sulfonate (compound ofFormula 1; 800BK or BK) and 800BK-NOS (compound ofFormula 2; 800NOS or NOS). -
FIGS. 13A-13C show whole animal imaging of dorsal and ventral view of a representative mouse injected with one of the dyes tested. Each panel of figures shows a dorsal and ventral view of the animal at 15 minutes, 1 hour, 2 hours, 4 hours 6 hours and 24 hours after injection. An animal injected with 800CW dye, 800NOS dye, and 800BK dye are shown inFIG. 13A ,FIG. 13B andFIG. 13C , respectively. -
FIG. 14 shows the whole animal LUT scale, theorgan 1/10th LUT scale, and theorgan 1/100th LUT scale. -
FIGS. 15A -15D show the signal intensity of the kidney (lower left corner), liver (lower right corner), lungs (upper left corner) and muscle (upper right corner) on theorgan 1/10th LUT scale. Organs from an animal injected with no probe (control), 800CW dye, 800NOS dye, and 800BK dye are shown inFIG. 15A ,FIG. 15B ,FIG. 15C , andFIG. 15D , respectively. -
FIGS. 16A-16D show the signal intensity of the kidney (lower left corner), liver (lower right corner), lungs (upper left corner) and muscle (upper right corner) on theorgan 1/100th LUT scale. Organs from an animal injected with no probe (control), 800CW dye, 800NOS dye, and 800BK dye are shown inFIG. 16A ,FIG. 16B ,FIG. 16C , andFIG. 16D , respectively. - The terms “a,” “an,” or “the” as used herein not only include aspects with one member, but also include aspects with more than one member. For example, an embodiment of a method of imaging that comprises using a compound set forth herein would include an aspect in which the method comprises using two or more compounds set forth herein.
- The term “approximately” or “about” as used herein to modify a numerical value indicates a defined range around that value. If “X” were the value, “approximately X” or “about X” would indicate a value from 0.9X to 1.1X, and more preferably, a value from 0.95X to 1.05X. Any reference to “approximately X” or “about X” specifically indicates at least the values X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. For example, “approximately X” or “about X” is intended to teach and provide written description support for a claim limitation of, e.g., “0.98X.”
- When the quantity “X” only allows whole-integer values (e.g., “X carbons”) and X is at most 15, “about X” indicates from (X-1) to (X+1). In this case, “about X” as used herein specifically indicates at least the values X, X-1, and X+1. If X is at least 16, the values of 0.90X and 1.10X are rounded to the nearest whole-integer values to define the boundaries of the range.
- When the modifier “approximately” or “about” is applied to describe the beginning of a numerical range, it applies to both ends of the range. Thus, “from approximately 700 to 850 nm” is equivalent to “from approximately 700 nm to approximately 850 nm.” Thus, “from about 700 to 850 nm” is equivalent to “from about 700 nm to about 850 nm.” When “approximately” or “about” is applied to describe the first value of a set of values, it applies to all values in that set. Thus, “about 680, 700, or 750 nm” is equivalent to “about 680 nm, about 700 nm, or about 750 nm.”
- “Balanced charge” as used herein includes the condition that the net charge for a compound and its associated counterions be zero under standard physiological conditions. In order to achieve a balanced charge, a skilled person will understand that after the first additional sulfonato group that balances the +1 charge of the indolinium ring, a cationic counterion (e.g., the cation of a Group I metal such as sodium) must be added to balance the negative charge from additional sulfonato groups. Similarly, anionic counterions must be added to balance any additional cationic groups (e.g., most basic amino groups under physiological conditions).
- While preferred embodiments of the invention are shown and described herein, such embodiments are provided by way of example only and are not intended to otherwise limit the scope of the invention. Various alternatives to the described embodiments of the invention may be employed in practicing the invention.
- Some advantages of cyanine dyes include: (1) cyanine dyes strongly absorb and fluoresce light; (2) many cyanine dyes do not rapidly photo-bleach under the fluorescence microscope; (3) many structures and synthetic procedures are available and the class of dyes is versatile; and (4) cyanine dyes are relatively small (a typical molecular weight is about 1,000 daltons) so they do not cause appreciable steric interference.
- Generally, cyanine dyes are prepared according to the procedures taught in Hamer, F. M., Cyanine Dyes and Related Compounds, Weissberger, Mass., ed. Wiley Interscience, N.Y. 1964. For example, U.S. Pat. Nos. 6,663,847; 6,887,854; 6,995,274; 7,504,089; 7,547,721; 7,597,878 and 8,303,936, incorporated herein by reference, describe synthesis mechanisms for a variety of cyanine dyes.
- Other cyanine dyes are known which contain reactive functional groups. For example, U.S. Pat. Nos. 4,337,063; 4,404,289 and 4,405,711, incorporated herein by reference, describe a synthesis for a variety of cyanine dyes having N-hydroxysuccinimide active ester groups. U.S. Pat. No. 4,981,977, incorporated herein by reference, describes a synthesis for cyanine dyes having carboxylic acid groups. U.S. Pat. No. 5,268,486, incorporated herein by reference, discloses a method for making arylsulfonate cyanine dyes. U.S. Pat. No. 6,027,709, incorporated herein by reference, discloses methods for making cyanine dyes having phosphoramidite groups. U.S. Pat. No. 6,048,982, incorporated herein by reference, discloses methods for making cyanine dyes having a reactive group selected from the group consisting of isothiocyanate, isocyanate, phosphoramidite, monochlorotriazine, dichlorotriazine, mono- or di-halogen substituted pyridine, mono- or di-halogen substituted diazine, aziridine, sulfonyl halide, acid halide, hydroxysuccinimide ester, hydroxy sulfosuccinimide ester, imido ester, glyoxal and aldehyde.
- As described herein, the present invention provides for the use of a cyanine dye of the compound having Formula 1:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation.
- In one embodiment, the present invention provides a solid form (a polymorph), which is Form A of
Formula 1. Form A ofFormula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°. Form A has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 4.3°, about 9.6°, about 12.9°, about 18.3°, and about 20.8°. Form A has an X-ray powder diffraction pattern substantially as shown inFIG. 1E . - In one embodiment, the present invention provides a solid form (a polymorph), which is Form B of
Formula 1. Form B ofFormula 1 has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 21.2°. Form B has an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 5.3°, about 14.2°, about 14.3°, about 20.7° and about 21.2°. Form B has an X-ray powder diffraction pattern substantially as shown inFIG. 1H . - In certain aspects, the polymorphs of the invention are formulated into a composition prior to administration to a subject.
- The compounds of
Formula 1 can exist in crystalline or noncrystalline form, or as a mixture thereof. For salts of the invention that are in crystalline form, the skilled artisan will appreciate that pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethylacetate. In one embodiment, the invention provides the sodium salt of the compound ofFormula 1 incorporated into the crystalline lattice. - In one aspect, the present invention provides a polymorph of the compound of
Formula 1 in isolated or pure form. “Isolated” or “pure” or “substantially pure” form refers to a sample in which the polymorph is present in an amount of >75%, particularly >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, or >99%, relative to other materials which may be present in the sample. - The polymorphs made according to the methods of the invention can be characterized by any methodology according to the art. For example, the polymorphs made according to the methods of the invention may be characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy, and spectroscopy (e.g., Raman, solid state nuclear magnetic resonance (ssNMR), and infrared (IR)).
- Polymorphs according to the invention may be characterized by X-ray powder diffraction patterns (XRPD). The relative intensities of XRPD peaks can vary, depending upon the sample preparation technique, the sample mounting procedure and the particular instrument employed. Moreover, instrument variation and other factors can affect the 2Θ values. Therefore, the XRPD peak assignments can vary by plus or minus about 0.2 degrees.
- The polymorph forms of the invention are useful in the production of imaging agents and can be obtained by means of a crystallization process to produce crystalline and semi-crystalline forms. In various embodiments, the crystallization is carried out by either generating the compound of
Formula 1 in a reaction mixture and isolating the desired polymorph from the reaction mixture, or by dissolving raw compound in a solvent, optionally with heat, followed by crystallizing/solidifying the product by cooling (including active cooling) and/or by the addition of an antisolvent for a period of time. The crystallization can be followed by drying carried out under controlled conditions until the desired water content is reached in the end polymorphic form. - In another embodiment, the present invention provides a method of making a polymorph of a compound of Formula 1 (Form A or Form B). In various embodiments, the invention is directed to methods of making a polymorph of the compound of
Formula 1, wherein the method involves converting an amorphous form into a desired polymorph. In certain embodiments, the methods comprise exposing a composition comprising an amorphous form to conditions sufficient to convert at least about 50% of the total amount of the amorphous form into at least about 50% of the desired polymorph, and isolating the desired polymorph as needed. - In certain instances, a crystalline solid will be more amenable to purification than an amorphous solid and the crystalline form is able to be made in higher purity. This is because, under proper conditions, the formation of the crystals tends to exclude impurities from the solid, in contrast to amorphous solids formed in a less controlled manner. Similarly, a crystalline solid will often have better stability than an amorphous solid, as the crystal packing gives a protective effect. For materials which are polymorphic, some crystal forms will normally be more effective than others at excluding impurities and enhancing stability.
- In one embodiment, the present invention provides for a composition according to Formula 2:
- or a hydrate or polymorph thereof and having a pharmaceutically acceptable cation.
- One embodiment of the invention includes a method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate compound of Formula 1:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation, wherein the administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's organ system to electromagnetic radiation; and detecting fluorescence radiation from the compound. In one embodiment, the organ includes one or more of kidney, bladder, liver, spleen, intestine, heart, lungs and muscle. In one embodiment, the organ is kidney, bladder or combinations of In another embodiment, the organ is the ureter of a kidney.
- In one embodiment, the method includes administering the compound of
Formula 1 intravenously. The compound ofFormula 1 can be administered as a bolus injection, e.g., an intravenous bolus injection. In some embodiments, about 5 mL to about 10 mL of a composition comprising the compound ofFormula 1 is administered in a bolus injection. - In one embodiment, the method includes administering the compound of
Formula 1 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium. - In one embodiment, the method includes administering the compound of
Formula 1 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution. - The compound of
Formula 1 can be highly soluble in water. In some embodiments, the compound ofFormula 1 is re-suspended in water to a concentration of at least 200 mg/mL, or about 300 mg/mL to about 320 mg/mL. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 3000.0 μg/kg and approximately 1500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1500.0 μg/kg and approximately 1000.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 1000.0 μg/kg and approximately 500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 500.0 μg/kg and approximately 170.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 170.0 μg/kg and approximately 120.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 120.0 μg/kg and approximately 60.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 1 at a diagnostic effective amount of the compound ranging between approximately 30.0 μg/kg and approximately 500.0 μg/kg. - The compounds of
Formula 1 can be non-toxic. They can absorb and fluoresce light, and do not rapidly photo-bleach under fluorescence imaging. Upon administration, the compounds ofFormula 1 can be transported to tissues and organs of the subject via the natural flow of bodily fluids in the subject. As such, compounds ofFormula 1 can be carried or transferred from the site of administration to the desired sites, tissues and organs for, e.g., visualization. - In certain embodiments, the compounds and methods herein can image the biliary tract which includes any part of the liver, gall bladder, spleen, small intestine, and associated ducts. In certain instances, the biliary tract includes the intrahepatic bile ducts, cystic duct—gallbladder to common bile duct—and common bile duct—liver and gallbladder to small intestine. In some instances, the compounds herein are found in a subject's bile or urine at a time period after administering. The present invention provides compositions of the compounds of
Formula - In certain embodiments, the methods herein provide visualizing the compounds of
Formula - In one embodiment, the method includes measuring a fluorescence intensity of the administered compound of
Formula 1 remaining at the tissue of the subject's organ at a time period after administering. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle. In one embodiment, the organ is kidney, bladder or combinations. In another embodiment, the organ is the ureter of a kidney. In some embodiments, the method includes measuring a fluorescence intensity of the administered compound ofFormula 1 remaining in the subject's urine or bile at a time period after administering. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 1 is background fluorescence approximately 24 hours after administering. - In one embodiment, the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, an endoscopic procedure, and an open procedure.
- In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 1 is higher in the kidney as compared to a measured fluorescence intensity of the administered compound ofFormula 1 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering. - In one embodiment, a pharmaceutical composition comprises a diagnostic imaging amount of a compound of
Formula 1, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier. - In another embodiment, a method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate of Formula 2:
- or a solvate or polymorph thereof and having a pharmaceutically acceptable cation, wherein the administering is performed at one or more times selected from the group consisting of before a procedure, during a procedure, after a procedure and combinations thereof, exposing tissue of the subject's organ system to electromagnetic radiation; and detecting fluorescence radiation from the compound. In one embodiment, the organ includes one or more of kidney, bladder, liver, spleen, intestine, heart, lungs and muscle. In one embodiment, the organ is a liver. In one embodiment, the organ is the biliary duct of a liver. In one embodiment, the organ is the cystic duct of a liver.
- In one embodiment, the method includes administering the compound of
Formula 2 intravenously. The compound ofFormula 2 can be administered as a bolus injection, e.g., an intravenous bolus injection. In some embodiments, about 5 mL to about 10 mL of a composition comprising the compound ofFormula 2 is administered in a bolus injection. - In one embodiment, the method includes administering the compound of
Formula 2 wherein the pharmaceutically acceptable cation is selected from the group consisting of potassium or sodium. - In one embodiment, the method includes administering the compound of
Formula 2 in combination with a pharmaceutically acceptable carrier selected from the group consisting of physiological sterile saline solution, sterile water solution, pyrogen-free water solution, isotonic saline solution, and phosphate buffer solution. - The compound of
Formula 2 can be highly soluble in water. In some embodiments, the compound ofFormula 2 is resuspended in water to a concentration of at least 200 mg/mL, about 300 mg/mL or about 320 mg/mL. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 3000.0 μg/kg and approximately 1500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1500.0 μg/kg and approximately 1000.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 1000.0 μg/kg and approximately 500.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 500.0 μg/kg and approximately 170.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 170.0 μg/kg and approximately 120.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 120.0 μg/kg and approximately 60.0 μg/kg. - In one embodiment, the method includes administering the compound of
Formula 2 at a diagnostic effective amount of the compound ranging between approximately 30.0 μg/kg and approximately 500.0 μg/kg. - The compounds of
Formula 2 can be non-toxic. They can absorb and fluoresce light, and do not rapidly photo-bleach under fluorescence imaging. Upon administration, the compounds ofFormula 2 can be transported to tissues and organs of the subject via the natural flow of bodily fluids in the subject. As such, compounds ofFormula 2 can be carried or transferred from the site of administration to the desired sites, tissues and organs for, e.g., visualization. - In one embodiment, the method includes measuring a fluorescence intensity of the administered compound of
Formula 2 remaining at the tissue of the subject's organ system at a time period after administering. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle. In one embodiment, the organ is the liver. In another embodiment, the organ is the biliary duct of a liver. In another embodiment, the organ is the cystic duct of a liver. In some embodiments, the method includes measuring a fluorescence intensity of the administered compound ofFormula 2 remaining in the subject's urine or bile at a time period after administering. - In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is background fluorescence approximately 24 hours after administering. - In one embodiment, the method includes the procedure selected from the group consisting of a laparoscopic procedure, a robotic procedure, a robotic laparoscopic procedure, an endoscopic procedure, and an open procedure.
- In one embodiment, the method includes the measured fluorescence intensity of the administered compound of
Formula 2 is higher in the liver as compared to a measured fluorescence intensity of the administered compound ofFormula 2 in one or more of the spleen, intestine, heart, lungs, muscle, or combinations thereof approximately up to six hours after administering. - In one embodiment, a pharmaceutical composition comprises a diagnostic imaging amount of a compound of
Formula 2, a pharmaceutically acceptable cation, and a pharmaceutically acceptable carrier. - In some embodiments, a pharmaceutical composition of compound of
Formula 1 or compound ofFormula 2 are in combination with a pharmaceutically acceptable cation and a pharmaceutically acceptable carrier in a diagnostic effective amount. In such embodiments, the pharmaceutical composition is contained in an intravenous drip bag. - In selected embodiments, the diagnostic effective amount of each of the compound of
Formula 1 and the compound ofFormula 2, is independently less than, for example, 3000.0, 2800.0, 2600.0, 2400.0, 2200.0, 2000.0, 1800.0, 1600.0, 1400.0, 1200.0, 1000.0, 950.0, 900.0, 850.0, 800.0, 750.0, 700.0, 650.0, 600.0, 550.0, 500.0, 490.0, 480.0, 470.0, 460.0, 450.0, 440.0, 430.0, 420.0, 410.0, 400.0, 390.0, 380.0, 370.0, 360.0, 350.0, 340.0, 330.0, 320.0, 310.0, 300.0, 290.0, 280.0, 270.0, 260.0, 250.0, 240.0, 230.0, 220.0, 210.0, 200.0, 190.0, 180.0, 170.0, 160.0, 150.0, 140.0, 130.0, 120.0, 110.0, 100.0, 95.0, 90.0, 85.0, 80.0, 75.0, 70.0, 65.0, 60.0, 55.0, 50.0, 49.0, 48.0, 47.0, 46.0, 45.0, 44.0, 43.0, 42.0, 41.0, 40.0, 39.5, 39.0, 38.5, 38.0, 37.5, 37.0, 36.5, 36.0, 35.5, 35.0, 34.5, 34.0, 33.5, 33.0, 32.5, 32.0, 31.5, 31.0, 30.9, 30.8, 30.7, 30.6, 30.5, 30.4, 30.3, 30.2, 30.1 μg/kg. - In selected embodiments, the diagnostic effective amount of each of the compound of
Formula 1 and the compound ofFormula 2, is independently greater than, for example, 2800.0, 2600.0, 2400.0, 2200.0, 2000.0, 1800.0, 1600.0, 1400.0, 1200.0, 1000.0, 950.0, 900.0, 850.0, 800.0, 750.0, 700.0, 650.0, 600.0, 550.0, 500.0, 490.0, 480.0, 470.0, 460.0, 450.0, 440.0, 430.0, 420.0, 410.0, 400.0, 390.0, 380.0, 370.0, 360.0, 350.0, 340.0, 330.0, 320.0, 310.0, 300.0, 290.0, 280.0, 270.0, 260.0, 250.0, 240.0, 230.0, 220.0, 210.0, 200.0, 190.0, 180.0, 170.0, 160.0, 150.0, 140.0, 130.0, 120.0, 110.0, 100.0, 95.0, 90.0, 85.0, 80.0, 75.0, 70.0, 65.0, 60.0, 55.0, 50.0, 49.0, 48.0, 47.0, 46.0, 45.0, 44.0, 43.0, 42.0, 41.0, 40.0, 39.5, 39.0, 38.5, 38.0, 37.5, 37.0, 36.5, 36.0, 35.5, 35.0, 34.5, 34.0, 33.5, 33.0, 32.5, 32.0, 31.5, 31.0, 30.9, 30.8, 30.7, 30.6, 30.5, 30.4, 30.3, 30.2, 30.1, 30.0 μg/kg. - In selected embodiments, the diagnostic effective amount of each of the compound of Formula 1 and the compound of Formula 2, is independently in the range from approximately 30.0 μg/kg to approximately 3000.0 μg/kg, approximately 30.1 μg/kg to approximately 2800.0 μg/kg, approximately 30.2 μg/kg to approximately 2600.0 μg/kg, approximately 30.3 μg/kg to approximately 2400.0 μg/kg, approximately 30.4 μg/kg to approximately 2200.0 μg/kg, approximately 30.5 μg/kg to approximately 2000.0 μg/kg, approximately 30.6 μg/kg to approximately 1800.0 μg/kg, approximately 30.7 μg/kg to approximately 1600.0 μg/kg, approximately 30.8 μg/kg to approximately 1400.0 μg/kg, approximately 30.9 μg/kg to approximately 1200.0 μg/kg, approximately 31.0 μg/kg to approximately 1000.0 μg/kg, approximately 31.5 μg/kg to approximately 950.0 μg/kg, approximately 32.0 μg/kg to approximately 900.0 μg/kg, approximately 32.5 μg/kg to approximately 850.0 μg/kg, approximately 33.0 μg/kg to approximately 800.0 μg/kg, approximately 33.5 μg/kg to approximately 750.0 μg/kg, approximately 34.0 μg/kg to approximately 700.0 μg/kg, approximately 34.5 μg/kg to approximately 650.0 μg/kg, approximately 35.0 μg/kg to approximately 600.0 μg/kg, approximately 35.5 μg/kg to approximately 550.0 μg/kg, approximately 36.0 μg/kg to approximately 500.0 μg/kg, approximately 36.5 μg/kg to approximately 490.0 μg/kg, approximately 37.0 μg/kg to approximately 480.0 μg/kg, approximately 37.5 μg/kg to approximately 470.0 μg/kg, approximately 38.0 μg/kg to approximately 460.0 μg/kg, approximately 38.5 μg/kg to approximately 450.0 μg/kg, approximately 39.0 μg/kg to approximately 440.0 μg/kg, approximately 39.5 μg/kg to approximately 430.0 μg/kg, approximately 40.0 μg/kg to approximately 420.0 μg/kg, approximately 41.0 μg/kg to approximately 410.0 μg/kg, approximately 42.0 μg/kg to approximately 400.0 μg/kg, approximately 43.0 μg/kg to approximately 390.0 μg/kg, approximately 44.0 μg/kg to approximately 380.0 μg/kg, approximately 45.0 μg/kg to approximately 370.0 μg/kg, approximately 46.0 μg/kg to approximately 360.0 μg/kg, approximately 47.0 μg/kg to approximately 350.0 μg/kg, approximately 48.0 μg/kg to approximately 340.0 μg/kg, approximately 49.0 μg/kg to approximately 330.0 μg/kg, approximately 50.0 μg/kg to approximately 320.0 μg/kg, approximately 55.0 μg/kg to approximately 310.0 μg/kg, approximately 60.0 μg/kg to approximately 300.0 μg/kg, approximately 65.0 μg/kg to approximately 290.0 μg/kg, approximately 70.0 μg/kg to approximately 280.0 μg/kg, approximately 75.0 μg/kg to approximately 270.0 μg/kg, approximately 80.0 μg/kg to approximately 260.0 μg/kg, approximately 85.0 μg/kg to approximately 250.0 μg/kg, approximately 90.0 μg/kg to approximately 240.0 μg/kg, approximately 95.0 μg/kg to approximately 230.0 μg/kg, approximately 100.0 μg/kg to approximately 220.0 μg/kg, approximately 110.0 μg/kg to approximately 210.0 μg/kg, approximately 120.0 μg/kg to approximately 200.0 μg/kg, approximately 130.0 μg/kg to approximately 190.0 μg/kg, approximately 140.0 μg/kg to approximately 180.0 μg/kg, and approximately 150.0 μg/kg to approximately 170.0 μg/kg.
- In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 3000.0 μg/kg to approximately 1500.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 1500.0 μg/kg to approximately 1000.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 1000.0 μg/kg to approximately 500.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 500.0 μg/kg to approximately 170.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 170.0 μg/kg to approximately 120.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 120.0 μg/kg to approximately 60.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 1 is in the range from approximately 30.0 μg/kg to approximately 500.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 3000.0 μg/kg to approximately 1500.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 1500.0 μg/kg to approximately 1000.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 1000.0 μg/kg to approximately 500.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 500.0 μg/kg to approximately 170.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 170.0 μg/kg to approximately 120.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 120.0 μg/kg to approximately 60.0 μg/kg. - In one embodiment, the diagnostic effective amount of the compound of
Formula 2 is in the range from approximately 30.0 μg/kg to approximately 500.0 μg/kg. - The diagnostic effective amount of each of the compound of
Formula 1 and the compound ofFormula 2 according to the invention is effective over a wide dosage range. The exact dosage will depend upon the route of administration, the form in which each compound is administered, the gender, age, and body weight of the subject to be treated, and the preference and experience of the administrator. - In selected embodiments, the fluorescence intensity of each of the administered compound of
Formula 1 and the administered compound ofFormula 2 may be independently measured at a time period of, for example, less than 24 hrs, 23 hrs, 22 hrs, 21 hrs, 20 hrs, 19 hrs, 18 hrs, 17 hrs, 16 hrs, 15 hrs, 14 hrs, 13 hrs, 12 hrs, 11 hrs, 10 hrs, 9.5 hrs, 9.0 hrs, 8.5 hrs, 8.0 hrs, 7.5 hrs, 7.0 hrs, 6.5 hrs, 6.0 hrs, 5.5 hrs, 5.0 hrs, 4.75 hrs, 4.50 hrs, 4.25 hrs, 4.00 hrs, 3.75 hrs, 3.50 hrs, 3.25 hrs, 3.00 hrs, 2.75 hrs, 2.50 hrs, 2.25 hrs, 2.00 hrs, 1.75 hrs, 1.50 hrs, 1.25 hrs, 1.00 hrs, 0.90 hrs, 0.80 hrs, 0.70 hrs, 0.60 hrs, 0.50 hrs, 0.40 hrs, 0.30 hrs, 0.20 hrs after administering. - In selected embodiments, the fluorescence intensity of each of the administered compound of
Formula 1 and the administered compound ofFormula 2 may be independently measured at a time period of, for example, greater than 23 hrs, 22 hrs, 21 hrs, 20 hrs, 19 hrs, 18 hrs, 17 hrs, 16 hrs, 15 hrs, 14 hrs, 13 hrs, 12 hrs, 11 hrs, 10 hrs, 9.5 hrs, 9.0 hrs, 8.5 hrs, 8.0 hrs, 7.5 hrs, 7.0 hrs, 6.5 hrs, 6.0 hrs, 5.5 hrs, 5.0 hrs, 4.75 hrs, 4.50 hrs, 4.25 hrs, 4.00 hrs, 3.75 hrs, 3.50 hrs, 3.25 hrs, 3.00 hrs, 2.75 hrs, 2.50 hrs, 2.25 hrs, 2.00 hrs, 1.75 hrs, 1.50 hrs, 1.25 hrs, 1.00 hrs, 0.90 hrs, 0.80 hrs, 0.70 hrs, 0.60 hrs, 0.50 hrs, 0.40 hrs, 0.30 hrs, 0.20 hrs, 0.10 hrs after administering. - In selected embodiments, the fluorescence intensity of each of the administered compound of
Formula 1 and the administered compound ofFormula 2 may be independently measured at a time period in the range from approximately 0.10 hrs to approximately 24 hrs, approximately 0.20 hrs to approximately 23 hrs, approximately 0.30 hrs to approximately 22 hrs, approximately 0.40 hrs to approximately 21 hrs, approximately 0.50 hrs to approximately 20 hrs, approximately 0.60 hrs to approximately 19 hrs, approximately 0.70 hrs to approximately 18 hrs, approximately 0.80 hrs to approximately 17 hrs, approximately 0.90 hrs to approximately 16 hrs, approximately 1.00 hr to approximately 15 hrs, approximately 1.25 hrs to approximately 14 hrs, approximately 1.50 hrs to approximately 13 hrs, approximately 1.75 hrs to approximately 12 hrs, approximately 2.00 hrs to approximately 11 hrs, approximately 2.25 hrs to approximately 10 hrs, approximately 2.50 hrs to approximately 9.5 hrs, approximately 2.75 hrs to approximately 9.0 hrs, approximately 3.00 hrs to approximately 8.5 hrs, approximately 3.25 hrs to approximately 8.0 hrs, approximately 3.50 hrs to approximately 7.5 hrs, approximately 3.75 hrs to approximately 7.0 hrs, approximately 4.00 hrs to approximately 6.5 hrs, approximately 4.25 hrs to approximately 6.0 hrs, approximately 4.50 hrs to approximately 5.5 hrs, approximately 4.75 hrs to approximately 5.0 hrs after administering. - In the embodiments of the methods described herein, the sample is illuminated with a wavelength of light selected to give a detectable optical response, and observed with a means for detecting the optical response. Equipment that is useful for illuminating the dye compounds of the invention includes, but is not limited to, tungsten lamps, hand-held ultraviolet lamps, mercury arc lamps, xenon lamps, light emitting diodes (LED), lasers and laser diodes. These illumination sources are optionally integrated into surgical cameras, laparoscopes and microscopes. Preferred embodiments of the invention are dyes that are excitable at or near the wavelengths 633-636 nm, 647 nm, 660 nm, 680 nm and beyond 700 nm, such as 780 nm, 810 nm and 850 nm as these regions closely match the output of relatively inexpensive excitation sources. The optical response is optionally detected by visual inspection, or by use of any of the following devices: CCD cameras, video cameras, photographic film.
- The NIR imaging probe used was the compound of
Formula 1; excitation 773 nm and emission 790 nm or independently,Formula 2, excitation 772 nm and emission 787 nm. - The compound of
Formula 1 and the compound ofFormula 2 as described herein can be administered in a manner compatible with the dosage formulation, and in such amount as will be effective or suitable for in vivo imaging. The quantity to be administered depends on a variety of factors including, e.g., the age, body weight, physical activity, and diet of the individual, the tissue or organ to be imaged, and type of procedure or surgery to be performed. In certain embodiments, the size of the dose may also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of the compound in a particular individual. - It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, hereditary characteristics, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- In certain embodiments, the dose may take the form of solid, semi-solid, or lyophilized powder forms, preferably in unit dosage forms suitable for simple administration of precise dosages. In some embodiments, the dose is provided in a container, vial or syringe at a particular dosage for one or more administrations.
- As used herein, the term “unit dosage form” refers to physically discrete units suitable as unitary dosages for humans and other mammals, each unit containing a predetermined quantity of an imaging agent calculated to produce the desired onset, tolerability, and/or fluorescent effects, in association with a suitable pharmaceutical excipient (e.g., an ampoule). In addition, more concentrated dosage forms may be prepared, from which the more dilute unit dosage forms may then be produced. The more concentrated dosage forms thus will contain substantially more than, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times the amount of the imaging agent.
- Methods for preparing such dosage forms are known to those skilled in the art (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ED., Mack Publishing Co., Easton, Pa. (1990)). The dosage forms typically include a conventional pharmaceutical carrier or excipient and may additionally include other medicinal agents, carriers, adjuvants, diluents, tissue permeation enhancers, solubilizers, and the like. Appropriate excipients can be tailored to the particular dosage form and route of administration by methods well known in the art (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ED., Mack Publishing Co., Easton, Pa. (1990)).
- In certain embodiments, the dosage forms contain a stabilizing agent for the storage, isolation, purification, and/or lyophilization of the compounds. Agents for lyophilization include, but are not limited to, a saccharide such as a monosaccharide, a disaccharide or dextran. Other saccharides include glucose, galactose, xylose, glucuronic acid, trehalose, dextran, hydroxyethyl starch, mannitol, or 5% dextrose.
- For parenteral administration, e.g., intravenous injection, intra-arterial injection, subcutaneous injection, intramuscular injection and the like, the effective dose can be in the form of sterile injectable solutions and sterile packaged powders. Preferably, injectable solutions are formulated at a pH of from about 4.5 to about 7.5, or physiological pH.
- In some embodiments, the effective dose for imaging contains a lyophilized compound described herein in a high-quality, easily dissolved form which is stable for months at room temperature. The lyophilized compound of
Formula 1 orFormula 2 can be stored in any suitable type of sealed container, such as a sealed vial or syringe that contains an amount of the compound for a single dosage for a subject, such as a human adult. The term “vial” is used broadly herein, to refer to any drug-packaging device that is designed and suitable for sealed and sterile storage, shipping, and handling of small (e.g., single-dosage) quantities of drugs. Single-chamber vials (which would contain only the lyophilized compound, with no water) are well known; a typical single-chamber vial may be designed for use with an intravenous infusion bag. Alternatively, two-chamber vials can be used that contain both the lyophilized compound and a sterile aqueous solution, to enable immediate reconstitution and injection of an aqueous liquid containing the compound ofFormula 1 orFormula 2. - Provided herein are kits containing a compound of
Formula 1 or a compound ofFormula 2. In some embodiments, a kit comprises one or more vials or syringes containing compound ofFormula 1 in, for example, a lyophilized form. In other embodiments, a kit comprises one or more vials or syringes containing compound ofFormula 2 in, for example, a lyophilized form. Such kits can also include a pharmaceutically acceptable carrier or a sterile aqueous solution, e.g., sterile water for reconstituting the compound prior to administration. In some cases, the kit also includes a sterile syringe for parenteral administration of the compound or for use with an intravenous infusion bag. The kit can also include an instruction manual for use. - When ranges are used herein, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. Use of the term “approximately” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary from, for example, between 1% and 15% of the stated number or numerical range. The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) includes those embodiments that “consist of” or “consist essentially of” the described features.
- The compound of
Formula 1 may be synthesized by dissolving 3,3-Dimethyl-2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-5-sulfo-1-(4-sulfobutyl)-3H-indolium hydroxide, innersalt, trisodium salt (1 g, 1.05 mmol) in 25 mL of water and sparging with nitrogen for 15 minutes. Sodium 4-hydroxybenzenesulfonate dihydrate (875 mg, 3.77 mmol) was dissolved in 3.6 mL 1N NaOH (3.6 mmol) and added to the reaction mixture. The reaction mixture was placed in an oil bath at 40° C. and stirred for 16 hours. The solution was dried by rotary evaporation and the product was then recrystallized from 80:20 ethanol:water. The compound was filtered then washed with ethanol and dried under vacuum at 60° C. for 18 hours. - The polymorph of the compound of Formula 1 (Form A) can be prepared as follows:
- A mixture of 3,3-Dimethyl-2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-5-sulfo-1-(4-sulfobutyl)-3H-indolium hydroxide, innersalt, trisodium salt (20 g, 21 mmol) and Sodium 4-hydroxybenzenesulfonate dihydrate (5.84 g, 25.2 mmol) is suspended in water (120 ml). The suspension is heated to 85° C. where complete dissolution is observed. Aqueous sodium hydroxide (10N, 2.5 ml, 25 mmol) is added dropwise and the reaction stirred for 45 min. Isopropanol (360 ml) is added slowly to maintain the reaction temperature above 60° C. The mixture is then slowly cooled to ambient temperature and the resulting slurry filtered. The filter cake is rinsed with 40 ml isopropanol:water (3:1) and twice with 40 ml isopropanol and dried at 50-60° C. under vacuum to obtain 18.4 g of the compound of
Formula 1 as a dark green solid. Ten grams (9 mmol) of this material is then recrystallized by dissolving in water (50 ml) and isopropanol (100 ml) at approximately 70° C., and slowly cooling the mixture to ambient temperature. The solids are collected by filtration and rinsed with 20 ml isopropanol:water (2:1) and twice with 20 ml isopropanol and dried at 50-60° C. under vacuum to obtain 6.7 g of thecompound Formula 1 as a crystalline dark green solid. - X-Ray Powder Diffraction (XRPD) for Form A
- XRPD analysis was carried out on a PANalytical X'pert pro, scanning the samples between 3 and 35° 20. The material was gently ground and loaded onto a multiwell plate with
- Kapton or mylar polymer film to support the sample. The multiwell plate was then loaded into a Panalytical diffractometer running in transmission mode and analyzed.
- The XRPD data are shown in
FIG. 1A-1F . As illustrated,FIG. 1A and 1C are identical and are both moderately crystalline and represent Form A.FIG. 1B is similar in crystallinity and is Form A. -
FIG. 1D is crystalline.FIG. 1E is an enlargment ofFIG. 1D .FIG. 1D andFIG. 1E represent Form A. -
FIG. 1F is the amorphous form. - Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 1 for Form A. Peak positions were measured and tabulated.
-
TABLE 1 Peak Data of IRDye 800BK Lot: BV736185 (FIG. 1A) XPRD Analysis d- Rel. Pos. Height FWHM spacing Int. [°2Th.] [cts] [°2Th.] [Å] [%] 4.2384 362.12 0.1279 20.84818 29.2 5.2771 550.29 0.0895 16.74659 44.37 5.4888 295.59 0.0768 16.10118 23.83 5.9607 293.22 0.0512 14.82759 23.64 9.5414 221.36 0.1535 9.26957 17.85 10.5728 314.69 0.0768 8.36752 25.37 10.9522 224.35 0.1023 8.07854 18.09 11.3914 371.25 0.0768 7.76803 29.93 11.9362 322.74 0.0768 7.41466 26.02 12.8323 579.36 0.0895 6.89882 46.71 14.1854 785.5 0.1279 6.24366 63.33 15.0743 305.87 0.1279 5.87743 24.66 15.3653 384.4 0.1279 5.76676 30.99 15.5532 262.25 0.1023 5.69752 21.15 15.8747 444.26 0.0512 5.58284 35.82 16.3152 405.54 0.1535 5.43308 32.7 16.7216 378.51 0.0768 5.30195 30.52 17.3776 514.77 0.064 5.10327 41.51 18.2698 226.8 0.1023 4.856 18.29 19.1518 465.59 0.1535 4.63431 37.54 19.5492 393.65 0.1279 4.54099 31.74 20.1805 277.83 0.1023 4.40035 22.4 20.7531 1146.9 0.1151 4.2802 92.47 21.2128 1240.24 0.1151 4.18848 100 21.8521 229.87 0.2047 4.06738 18.53 22.6123 239.17 0.1535 3.93232 19.28 23.389 331.71 0.064 3.80346 26.75 23.8748 148.63 0.1535 3.72716 11.98 24.3664 124.78 0.1535 3.65307 10.06 24.9407 221.2 0.1279 3.57024 17.84 26.4158 297.98 0.1279 3.37412 24.03 28.658 136.22 0.1791 3.11503 10.98 - Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 2 for Form A. Peak positions were measured and tabulated.
-
TABLE 2 Peak data of IRDye 800BK Lot: VE-759-24-1 (FIG. 1E) XRPD Analysis Pos. Height FWHM d-spacing Rel. Int. [°2Th.] [cts] [°2Th.] [Å] [%] 4.272 1845.05 0.064 20.68408 100 9.6191 863.9 0.0895 9.19491 46.82 10.5611 267.84 0.1023 8.37677 14.52 12.4823 217.24 0.0768 7.09145 11.77 12.7274 748.04 0.0895 6.95545 40.54 12.93 1108.7 0.0768 6.84692 60.09 13.4567 353.68 0.1279 6.58007 19.17 14.197 188.01 0.1023 6.23861 10.19 15.4372 537.33 0.064 5.74009 29.12 15.8734 703.35 0.0384 5.58329 38.12 16.1055 637.51 0.064 5.50336 34.55 16.6046 222 0.1279 5.33906 12.03 17.1929 293.61 0.1023 5.15766 15.91 17.559 419.11 0.1023 5.05094 22.72 18.0101 705.32 0.1023 4.92543 38.23 18.2864 1035.04 0.1663 4.85163 56.1 18.7831 635.82 0.0512 4.72445 34.46 19.1781 617.24 0.0895 4.62801 33.45 19.4323 420.97 0.4093 4.56805 22.82 19.7836 680.51 0.064 4.48772 36.88 20.2392 744.22 0.0512 4.38771 40.34 20.5039 801.47 0.1151 4.33166 43.44 20.8076 960.22 0.1407 4.26912 52.04 21.1497 546.41 0.1791 4.20083 29.61 21.7763 541.2 0.064 4.08136 29.33 22.5703 573.98 0.0512 3.93954 31.11 23.1948 292.69 0.1023 3.83487 15.86 23.6245 311.01 0.1279 3.76608 16.86 24.6218 243.08 0.1535 3.61575 13.17 25.2623 343.69 0.1791 3.52551 18.63 26.3234 274.93 0.1791 3.38575 14.9 28.0536 225.6 0.1535 3.18075 12.23 28.6694 301.22 0.2047 3.11382 16.33 - In one embodiment, it is possible to make Form B from Form A. Form A is crystalline and exists as small birefringent particles with no defined morphology. The material is hygroscopic (27 wt % uptake up-to 90%RH) and can change form under stress conditions. A form change does occur when Form A is subjected to 40° C./75% RH. This form corresponds with the form found with the post-GVS sample. HPLC purity showed no change.
-
FIG. 1H andFIG. 1I represent Form B. For comparison,FIG. 1G is identical toFIG. 1D . - Characteristic XRPD angles and d-spacings for the solid state form are summarized in Table 3 for Form B. Peak positions were measured and tabulated.
-
TABLE 3 Peak data of IRDye 800BK Lot: VE-759-24-1 Form B XRPD Analysis Pos. FWHM d-spacing Rel. Int. [°2Th.] Height [cts] [°2Th.] [Å] [%] 5.2989 1193.55 0.064 16.67783 52.81 5.9816 649.44 0.0512 14.77594 28.74 9.535 387.23 0.064 9.27578 17.13 10.6007 690.31 0.1023 8.3456 30.55 10.9387 376.49 0.0895 8.08848 16.66 11.3924 413.39 0.064 7.76734 18.29 11.9715 817.54 0.0768 7.39285 36.18 12.8677 587.96 0.1279 6.8799 26.02 14.2153 1273.22 0.0936 6.22544 56.34 14.2827 1000.8 0.078 6.21161 44.28 15.9468 606.88 0.2496 5.55317 26.85 16.3781 600.12 0.1092 5.4079 26.55 16.7597 562.34 0.1092 5.28561 24.88 17.3714 797.24 0.078 5.10083 35.28 17.7698 277.37 0.1872 4.98736 12.27 18.4312 246.4 0.156 4.80986 10.9 18.6816 475.06 0.1872 4.74595 21.02 19.1392 766.24 0.078 4.63351 33.91 19.5987 600.29 0.0936 4.52589 26.56 20.1626 509.11 0.0624 4.40057 22.53 20.7073 1255.16 0.1404 4.28603 55.54 21.2464 2259.95 0.1092 4.17848 100 21.8382 456.8 0.156 4.06656 20.21 22.6653 385.85 0.1872 3.92 17.07 23.4295 644.04 0.2808 3.79383 28.5 23.9381 351.56 0.1872 3.71438 15.56 24.9551 451.86 0.2184 3.56525 19.99 26.4745 574.6 0.0468 3.36399 25.43 - The compound of
Formula 2 may be synthesized by dissolving 3,3-Dimethyl-2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-2H-indol-2-ylidene]-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-5-sulfo-1-(4-sulfobutyl)-3H-indolium hydroxide, innersalt, trisodium salt (1 g, 1.05 mmol) in 25 mL of water and sparging with nitrogen for 15 minutes. Sodium phenoxide trihydrate (390 mg, 2.29 mmol) was dissolved in 2 mL ultrapure water and added to the reaction mixture. The reaction mixture was placed in an oil bath at 40° C. and stirred for 4 hours. The solution was dried by rotary evaporation and the product was then recrystallized from 90:10 ethanol:water. The compound was filtered then washed with ethanol and dried under vacuum at 60° C. for 18 hours. - The structure of the compound of comparative example 1, also referred to as 800CW, is shown below:
- The structure of indocyanine green (ICG) dye is shown below:
- In vitro cell-based assays with two carcinoma cell lines (A431 and A549) were done to assess non-specific binding of the compound of
Formula 1 and the compound ofFormula 2. The dyes were compared to 800CW. This is shown inFIGS. 2A, 2B, and 2C . - The compound of
Formula 2 demonstrated a significant increase in non-specific binding compared to either the compound ofFormula 1 and 800CW by two-fold. The compound ofFormula 1 was more comparable to 800CW. - To confirm all three compounds have comparable fluorescence, a dilution series was made and imaged on an Odyssey SA fluorescence imaging system (LI-COR Biosciences). The fluorescence in each well was quantified with the instrument software.
FIG. 2C shows that all three compounds in this test were very close in fluorescence, thus confirming that the increased fluorescence at higher concentrations noted in plate-based assay is likely due to a tendency of the compound to bind non-specifically to cells. - In general, low non-specific binding is an advantage. Both cell lines show low non-specific binding for all compounds at concentrations below 1 μM. However all begin to show some binding at higher concentrations.
- Animals injected with the probes were imaged over time using the 800 fluorescence channel of the Pearl Impulse Imaging System (LI-COR Biosciences). Clearance profiles for 800CW, the compound of
Formula 1, and the compound ofFormula 2 were carried out in nude mice (dose of 1 nmole for all compounds). Serial images and excised organs were evaluated over a 24 hr period. Dorsal image series are presented inFIG. 3 . A Pearl Impulse small animal imaging system was used for all animal and organ image acquisitions. - The compound of comparative example 1 is used as the reference. From the Dorsal view there is no kidney signal for any probe. At 2 hrs post injection, the compound of
Formula 2 exhibits high signal, emanating in the liver region visible from the back. The compound ofFormula 2 never fully disseminates because it is collected rapidly in the liver and by 5 hr post injection, the whole body signal is low compared to 800CW and the compound ofFormula 1. - Ventral images are presented in
FIG. 4 . From visual examination, the compound ofFormula 1 and 800CW are similar in their clearance pattern. These two probes appear to clear rapidly via the kidney. This feature is very useful for imaging the urinary system. - The compound of
Formula 2, on the other hand, clears through the liver. This feature is a very useful attribute for a biliary duct monitoring dye which may “mimic” ICG that is currently used for this clinical application. From the in vitro plate-based assays it appeared both the compound ofFormula 1 and the compound ofFormula 2 have similar fluorescence intensities to 800CW. However, from the in vivo data, it appeared that the compound ofFormula 1 moves rapidly through the tissues but is retained for an extended period in organs. - Bladder signal is the strongest signal noted for 800CW and the compound of
Formula 1 probes (purple arrows). - Whole body fluorescence numbers for the three probes (ventral view) are shown in
FIG. 5 . Non-invasive imaging will not capture signals for the full depth of the animal but the intensity values are useful to show a relative trend. - There is a slower clearance for 800CW and the compound of
Formula 1 as compared to the compound ofFormula 2. The signal for the compound ofFormula 2 appears to be lower overall than the signal for 800CW and the compound ofFormula 1, however, it appears to rapidly collect in the liver. At 24 hrs post administration, the remaining fluorescence is diminished for all three probes to roughly the same extent. - Another way of examining fluorescence signals is by measuring the % of the compound remaining at a particular time point. The 30 min time point is the baseline to which other time points are normalized. This data are presented below in Table 4.
-
30 min 120 min 300 min 1440 min Compound of comparative 100 85 23 0.8 example 1 (800CW) Compound of Formula 1100 81 19 1.4 (800BK-sulfonate) Compound of Formula 2100 70 14 1.4 (800BK-NOS) - The percent signal remaining at each time is shown with the 30 min time point post-injection, which is used as the baseline.
- The greatest reduction occurs for the compound of
Formula 2 at 2 hrs. The compound ofFormula 1 is very similar to 800CW and by 24 hrs post injection, all compounds are very similar in remaining signals at less than 2% of baseline. - Organs were excised at 24 hrs and imaged. Data is presented in
FIG. 6 . - The compound of
Formula 1 is retained at higher levels in the liver and kidney compared to the compound ofFormula 2 at 24 hrs post injection. Surprisingly, the compound ofFormula 2, which clears predominantly from the liver, has lower liver signals at 24 hrs when compared to 800CW and the compound ofFormula 1. This may be explained by a slower overall clearance from tissue for the compound ofFormula 1 as compared to 800CW and the compound ofFormula 2. - None of 800CW or the compound of
Formula 1 or the compound ofFormula 2 is detected in the brain and is likely due to their inability to cross the blood brain barrier. -
FIG. 7 illustrates the ureters along with kidney and bladder. When the compound ofFormula 1 was administered to screen the ureter of the kidney, an image of the region was captured post-administration. -
FIG. 8 illustrates fluorescence images of stained electrophoresis gels of selected proteins showing non-specific or affinity of the named compounds to human (H), bovine (B), ovalbumin (O), or 5% FBS (fetal bovine serum). It is clear that the compound ofFormula 2 has potential to be useful for biliary duct examinations, similar to ICG. - With the primary elimination route being renal for the compound of
Formula 1, the urine output in mice was analyzed. Urine was obtained from mice that received: neither of the compound ofFormula 1 nor the compound of Formula 2 (control), the compound ofFormula 1, ICG, and the compound ofFormula 2. The urine was extracted with an acetonitrile:methanol mix and imaged on an Odyssey CLx imager (LI-COR Biosciences) as shown inFIG. 9 . - No fluorescent signal was seen for the control and ICG. ICG is eliminated by the liver so no signal is expected. There was a slight fluorescence for the compound of
Formula 2 that suggests liver excretion is not quite exclusive. - A comparison between the compound of
Formula 2 and ICG was conducted for their common application in imaging the biliary duct (FIGS. 10A and 10B ). A Pearl Impulse small animal imaging system was used for all animal and organ image acquisitions. ICG is not very soluble in aqueous media and gives a much weaker fluorescent signal than the compound ofFormula 2 in vivo. A 50 nmole solution of ICG in phosphate buffer saline solution was prepared, injected intravenously, and compared for localization with a 1 nmole solution of the compound ofFormula 2 at time periods of 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs. - A comparison of the dose responses for the compound of
Formula 2 are shown inFIG. 10B (1 nmole),FIG. 10C (0.5 nmole), andFIGS. 10D and 10E (0.1 nmole) at time periods of 1 min, 30 min, 2 hrs, 5 hrs, and 24 hrs. All images are presented using the same LUT table exceptFIG. 10E where the LUT forFIG. 10D has been reduced to brighten the 800nm signal so they are visible. - The gall bladder is visible by 30 min post-intravenous administration for the 1 nmole (
FIG. 10B ) and 0.5 nmole (FIG. 10C ) doses and continues to be visible in the 2 hrs and 5 hrs images. The images for the 0.1 nmole dose inFIG. 10D appear to show very low detection signal using the same scale as the 1 nmole and 0.5 nmole dose series. However, if the scale is adjusted as inFIG. 10E , the gall bladder target region is visible on a very low background. A wide range of dosing is possible to accommodate a particular imaging system or application. - Fluorescent signal intensities of various organs were examined at 24 hrs and 72 hrs for the compound of
Formula 1 and the compound of Formula 2 (FIG. 11A-11E ). Organs examined included: heart (Ht), lungs (Ln), kidney (Kd), liver (Lv), spleen (Spl), intestine (Int), brain (Br), and muscle (Ms). At 24 hrs, there remains some signal in the liver and kidney but by 72 hrs the signal is diminished substantially. -
FIG. 11A shows the results using the control (800CW), 24 hours post administration. -
FIG. 11B shows the results using a compound ofFormula FIG. 11C shows the results using a compound ofFormula -
FIG. 11D-11E show theresults 72 hours post administration ofFormula 2 andFormula 1, respectively. -
FIG. 11F shows a surgically opened animal for determining whether biliary structures are visible. The animal's liver was positioned to expose the critical structures. The image series ofFIG. 11F-11H present the white light image of the liver with lobes raised to expose the gall bladder and biliary duct associated with Calot's triangle; the 800 nm image as detected by fluorescence studies of a compound ofFormula 2; and a composite image overlaying the 800 nm image atop the white light image. - This example describes an experiment to evaluate the excretion of the dyes described herein from animals injected with such. The dyes tested were stable cyanine dyes (IRdyes): 800CW, 800BK-sulfonate (compound of
Formula 1; 800BK or BK) and 800BK-NOS (compound ofFormula 2; 800NOS or NOS). In this study 12 nude mice (3 per treatment group) were injected with either (1) no probe (control group); (2) 800CW; (3) 800NOS; or (4) 800BK. The three probes (800CW-1166 g/mole (should have been 1091.1 g/mole), 800NOS-1011.09 g/mole, and 800BK-1113.14 g/mole) were dissolved in PBS. A spot test of the three probes was performed to detect the fluorescent signal when diluted to the injection dose of 1 nmole/100 μl (FIG. 12 ). The fluorescence of 800CW was slightly higher than that of 800NOS and 800BK. - The mice received 1 nmole of dye by tail vein injection. The mice were imaged serially over 24 hours after IV injection: 5 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 24 hours after injection. A representative series of images are presented in
FIGS. 13A -13C of one animal per dye. All the data was normalized to the same LUT. A control mouse (no probe) was used as a reference (no signal control). Imaging was performed using the Pearl® Trilogy Imaging System (LI-COR®). - The mice were then sacrificed and their organs and tissue (i.e., liver, kidney, lungs, spleen and muscle) were harvested. The organs were imaged to detect fluorescence. When the same LUT was used for the animal and organ images, fluorescence in the organs was not detectable. As such, the low end of the animal scale was expanded such that the images of the organs could be evaluated (
FIG. 14 ). For example, the “Organs 1/10th scale” was used for the images ofFIGS. 15A-15D and the “Organs 1/100th scales was used for the images ofFIGS. 16A-16D . -
FIG. 15A shows no fluorescence in the organs of the control animal. Kidneys (lower left corner) and liver (lower right corner) had a detectable signal in the animals treated with 800CW (FIG. 15B ), 800NOS (FIG. 15C ), and 800BK (FIG. 15D ). No muscle (top right corner) or lung tissue (top left corner) was visible in the treatments except for the 800CW treatment. At the 1/10th LUT scale, the high level is 1/10th that of the whole animal LUT scale. The data shows that there is only residual dye remaining in these organs when imaging at the whole animal LUT scale. -
FIGS. 16A-D show some signal in the organs if the whole animal LUT scale is reduced to 100× such that the adjusted scale is 1/100th the whole animal scale.FIG. 16A shows the signal from the control animal.FIGS. 16B, 16C and 16D shows the signal from organs of the 800CW treated animal, the 800NOS treated animal and the 800BK treated animal, respectively. - 800CW and 800BK was excreted renally. The higher overall signal in the 800CW animals is mainly due to the accidentally higher concentration of the probe injected into the animals.
- 800NOS was eliminated from the body via the biliary tract (liver, gall bladder and bile ducts) and intestines. In the 800NOS treated animals, the liver was visible at 15 minutes and then the gall bladder, as the dye rapidly left the liver. The data also showed that the dye was moved into the intestines for excretion. The predominant signal between 2-6 hours was in the intestines. At 24 hours post injection the intestinal signal was barely detectable.
- The organs were imaged under three LUT scales; each being progressively smaller in the signal range covered. The lower levels of each progressive scale were expanded to cover the full red to blue color range (
FIG. 14 ). Very little signal remained in any of the target organs such as liver, kidney, lungs and muscle. Similar signal intensities were found in the kidney for 800CW and 800BK. In the liver, 800BK had a higher signal compared to 800CW. The results show that 800BK has a longer retention time in the liver compared to 800CW and 800NOS. This may be due to increased (higher) plasma protein binding of 800BK than 800CW. - This example shows that the clearance of IRDye 800NOS is rapid from the whole body to the biliay system with a very short retention time in the liver and also rapid excretion into the intestines. The rapid clearance by the liver implies that 800NOS has low plasma protein binding activity.
- The pharmaceutical formulation of
Formula 1 is dissolved in a vial (25 mg) with 5 mL of saline (0.9% sodium chloride) and is administered to a patient via a bolus injection at the concentration of 5 mg/mL, 15 minutes prior to the surgery. The medical device for this procedure is the PINPOINT Endoscopic Fluorescence Imaging System (Novadaq, Mississauga, Ontario, Canada). At any point during the procedure, when the surgeon needs to identify the ureter, the device's mode is switched to the near-infrared detection imaging, and the surgeon visualizes the ureter via the monitor or display of the medical device. This identification of the ureter is visualized on the monitor as an overlay image, in which the surgeon can simultaneously locate the ureter with white light imaging. - The pharmaceutical formulation of
Formula 2 is dissolved in a vial (25 mg) with 5 mL of saline (0.9% sodium chloride) and is administered to a patient via a bolus injection at the concentration of 5 mg/mL, 15 minutes prior to the surgery starting. The medical device for this procedure is the da Vinci Firefly Surgical System (Intuitive Surgical, Sunnyvale Calif.). During the procedure, when the surgeon needs to identify the biliary duct, the device's mode is switched to the near-infrared detection imaging, and the surgeon identifies the biliary duct via the monitor or display of the medical device by switching between the white light image and the near-infrared image as needed. - It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/687,479 US20200078474A1 (en) | 2014-11-26 | 2019-11-18 | Ir dyes for fluorescence imaging |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462084971P | 2014-11-26 | 2014-11-26 | |
US14/949,654 US10548991B2 (en) | 2014-11-26 | 2015-11-23 | IR dyes for fluorescence imaging |
US16/687,479 US20200078474A1 (en) | 2014-11-26 | 2019-11-18 | Ir dyes for fluorescence imaging |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/949,654 Continuation US10548991B2 (en) | 2014-11-26 | 2015-11-23 | IR dyes for fluorescence imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200078474A1 true US20200078474A1 (en) | 2020-03-12 |
Family
ID=54848900
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/949,654 Expired - Fee Related US10548991B2 (en) | 2014-11-26 | 2015-11-23 | IR dyes for fluorescence imaging |
US16/687,479 Abandoned US20200078474A1 (en) | 2014-11-26 | 2019-11-18 | Ir dyes for fluorescence imaging |
US16/687,450 Active 2036-01-31 US11167046B2 (en) | 2014-11-26 | 2019-11-18 | IR dyes for fluorescence imaging |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/949,654 Expired - Fee Related US10548991B2 (en) | 2014-11-26 | 2015-11-23 | IR dyes for fluorescence imaging |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/687,450 Active 2036-01-31 US11167046B2 (en) | 2014-11-26 | 2019-11-18 | IR dyes for fluorescence imaging |
Country Status (10)
Country | Link |
---|---|
US (3) | US10548991B2 (en) |
EP (1) | EP3223861A1 (en) |
JP (2) | JP6673917B2 (en) |
CN (1) | CN106999609B (en) |
AR (1) | AR102743A1 (en) |
AU (1) | AU2015353700B2 (en) |
CA (1) | CA2964963A1 (en) |
HK (1) | HK1247812A1 (en) |
TW (1) | TWI737587B (en) |
WO (1) | WO2016085884A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11787764B2 (en) | 2018-02-15 | 2023-10-17 | Children's National Medical Center | Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR102743A1 (en) | 2014-11-26 | 2017-03-22 | Li Cor Inc | CONTRAST MEANS GO FOR FLUORESCENCE IMAGES |
US10758631B2 (en) | 2017-04-11 | 2020-09-01 | Li-Cor, Inc. | Solid cyanine dyes |
EP3609543A1 (en) * | 2017-04-11 | 2020-02-19 | Li-Cor, Inc. | Solid cyanine dyes |
JP7372319B2 (en) * | 2018-06-14 | 2023-10-31 | パーフュージョン テック アーペーエス | System and method for automated perfusion measurements |
CN110408233B (en) * | 2019-07-17 | 2020-04-03 | 北京大学 | P-sulfophenoxy cyanine dye and preparation method and application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55116259A (en) | 1979-03-01 | 1980-09-06 | Fuji Photo Film Co Ltd | Microimmunoassay method |
EP0047472B1 (en) | 1980-09-02 | 1985-04-24 | Fuji Photo Film Co., Ltd. | Method for immunochemical measurement of trace components |
JPS5745460A (en) | 1980-09-02 | 1982-03-15 | Fuji Photo Film Co Ltd | Inspection sheet for measuring trace component and inspecting method using said sheet |
US6086737A (en) * | 1984-03-29 | 2000-07-11 | Li-Cor, Inc. | Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes and suitable labels therefor |
US6048982A (en) | 1986-04-18 | 2000-04-11 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
US4981977A (en) | 1989-06-09 | 1991-01-01 | Carnegie-Mellon University | Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups |
JPH06145539A (en) | 1992-11-04 | 1994-05-24 | Fuji Photo Film Co Ltd | Cyanine compound |
US6027709A (en) | 1997-01-10 | 2000-02-22 | Li-Cor Inc. | Fluorescent cyanine dyes |
US7547721B1 (en) | 1998-09-18 | 2009-06-16 | Bayer Schering Pharma Ag | Near infrared fluorescent contrast agent and fluorescence imaging |
JP2000095758A (en) | 1998-09-18 | 2000-04-04 | Schering Ag | Near-infrared, fluorescent contrast medium, and its production |
US7597878B2 (en) | 2000-09-19 | 2009-10-06 | Li-Cor, Inc. | Optical fluorescent imaging |
DE60116510T2 (en) | 2000-09-19 | 2006-07-13 | Li-Cor, Inc., Lincoln | cyanine |
US6663847B1 (en) | 2000-10-13 | 2003-12-16 | Mallinckrodt Inc. | Dynamic organ function monitoring agents |
US7993927B2 (en) | 2006-07-03 | 2011-08-09 | Beth Israel Deaconess Medical Center, Inc. | Histology methods |
US20080154102A1 (en) | 2006-07-03 | 2008-06-26 | Frangioni John V | Intraoperative imaging methods |
WO2010057944A1 (en) | 2008-11-20 | 2010-05-27 | Ge Healthcare As | Dye conjugate imaging agents |
SG2014009146A (en) * | 2009-02-06 | 2014-05-29 | Beth Israel Hospital | Charge-balanced imaging agents |
CA2847887A1 (en) | 2011-09-23 | 2013-03-28 | Li-Cor, Inc. | Application of reduced dyes in imaging |
AR102743A1 (en) | 2014-11-26 | 2017-03-22 | Li Cor Inc | CONTRAST MEANS GO FOR FLUORESCENCE IMAGES |
US10758631B2 (en) | 2017-04-11 | 2020-09-01 | Li-Cor, Inc. | Solid cyanine dyes |
-
2015
- 2015-11-20 AR ARP150103806A patent/AR102743A1/en unknown
- 2015-11-23 WO PCT/US2015/062212 patent/WO2016085884A1/en active Application Filing
- 2015-11-23 CN CN201580064045.8A patent/CN106999609B/en not_active Expired - Fee Related
- 2015-11-23 EP EP15808306.3A patent/EP3223861A1/en not_active Withdrawn
- 2015-11-23 AU AU2015353700A patent/AU2015353700B2/en not_active Ceased
- 2015-11-23 CA CA2964963A patent/CA2964963A1/en not_active Abandoned
- 2015-11-23 JP JP2017527921A patent/JP6673917B2/en not_active Expired - Fee Related
- 2015-11-23 US US14/949,654 patent/US10548991B2/en not_active Expired - Fee Related
- 2015-11-25 TW TW104139216A patent/TWI737587B/en not_active IP Right Cessation
-
2018
- 2018-03-06 HK HK18103207.3A patent/HK1247812A1/en unknown
-
2019
- 2019-11-18 US US16/687,479 patent/US20200078474A1/en not_active Abandoned
- 2019-11-18 US US16/687,450 patent/US11167046B2/en active Active
-
2020
- 2020-03-04 JP JP2020036477A patent/JP7007412B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11787764B2 (en) | 2018-02-15 | 2023-10-17 | Children's National Medical Center | Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems |
Also Published As
Publication number | Publication date |
---|---|
US20200085976A1 (en) | 2020-03-19 |
AU2015353700B2 (en) | 2021-09-16 |
AU2015353700A1 (en) | 2017-06-29 |
JP7007412B2 (en) | 2022-01-24 |
JP2018502829A (en) | 2018-02-01 |
US10548991B2 (en) | 2020-02-04 |
EP3223861A1 (en) | 2017-10-04 |
WO2016085884A1 (en) | 2016-06-02 |
CA2964963A1 (en) | 2016-06-02 |
JP6673917B2 (en) | 2020-03-25 |
TW201634593A (en) | 2016-10-01 |
CN106999609B (en) | 2021-04-13 |
JP2020109099A (en) | 2020-07-16 |
AR102743A1 (en) | 2017-03-22 |
HK1247812A1 (en) | 2018-10-05 |
US11167046B2 (en) | 2021-11-09 |
CN106999609A (en) | 2017-08-01 |
US20160144058A1 (en) | 2016-05-26 |
TWI737587B (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11167046B2 (en) | IR dyes for fluorescence imaging | |
US10350310B2 (en) | Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition | |
JP2012520856A (en) | Optical imaging agent | |
US20080154102A1 (en) | Intraoperative imaging methods | |
WO2018191261A1 (en) | Solid cyanine dyes | |
US10758631B2 (en) | Solid cyanine dyes | |
WO2021158820A1 (en) | Nerve-specific fluorophore formulations for direct and systemic administration | |
EP4084829A1 (en) | Oxazine-based water-soluble fluorophore compounds for in vivo nerve imaging | |
JP2023537627A (en) | Compounds and compositions for tumor detection and surgical guidance | |
JP2023502998A (en) | pH-Sensitive Compositions, Formulations, and Methods of Tumor Imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MIDCAP FINANCIAL TRUST, MARYLAND Free format text: SECURITY INTEREST;ASSIGNOR:LI-COR, INC.;REEL/FRAME:058293/0889 Effective date: 20211201 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |